[ADDRESS_691649]-Line Therapy
[STUDY_ID_REMOVED]
March 17, 2022
2 CUMC IRB#:  AAAR3554  
Version Date:  10/19/2020  
TITLE : Phase II Open -Label, Single -Center Study Evaluating Safety and Efficacy  of 
Pembrolizumab Following Induction with the Hypomethylating Agent Azacitidine in  Patients 
with Advanced Pancreatic Cancer After Failure of First -Line Therapy.  
Coordinating  Center:  Columbia University Medical  Center  
Principal  Investigator : [INVESTIGATOR_532704] , M.D. . PhD  
Columbia University Medical  Center  
Herbert Irving Comprehensive Cancer  Center 
[ADDRESS_691650], 8th floor  
[LOCATION_001], NY ,[ZIP_CODE]
 Phone:  [PHONE_11032]
 Fax: 212 -305-3035  
Email address:  raw21 [EMAIL_10188]  
Co-Investigators:  Richard D. Carvajal,  M.D.  
Susan Bates,  M.D.  
Gulam Manji, M.D.,  Ph.D. 
 Antonio Fojo,  M.D. 
Statistician:  Shing Lee, Ph.D.  
[ADDRESS_691651], 6th Floor, Room  645
[LOCATION_001], NY  [ZIP_CODE]  
Phone:  [PHONE_11033]  
Email address:  [EMAIL_2915]  
3 Initial version: July 22,  2016  Regulatory  Sponsor:  Ruth White , M.D., PhD.  
Columbia University Medical  Center  
Herbert Irving Comprehensive Cancer  Center 
Email address:  [EMAIL_10189] u 
[ADDRESS_691652], 8th floor  
[LOCATION_001], NY  [ZIP_CODE] Phone:  [PHONE_11032]  
Funding  Source:  [COMPANY_006] & Co.,  Inc. One [COMPANY_006]  Drive  
[PO_BOX] 
Whitehouse Station, New Jersey  [ZIP_CODE]  
Study  Agent:  Pembrolizumab,  Keytruda  
Other  Agent:  Azacitidine,  Vidaza  
IND Status:  IND #: ###### 
IND Sp
onsor: Columbia Unive rsity M edical Center 
[ADDRESS_691653] read and  
understand the information in the Investigators’ Brochure (or Manufacturer’s Brochure) 
regarding the  risks and potential benefits. I will promptly submit the protocol to the applicable 
IRB for review  and approval. Once the protocol has be en approved by [CONTACT_1201], I understand 
that any  modification made during the course of the study must first be approved by [CONTACT_1201], 
prior to  implementation except when such modification is made to remove an immediate hazard 
to the subject. I  certify that I, and the study staff, have received the requisite training to conduct 
this research protocol.  I agree to maintain adequate and accurate records in accordance with 
Columbia University  and Herbert Irving Comprehensive Cancer Center policies, F ederal, state 
and local laws  and regulations. I agree to maintain the confidentiality of all information 
received or developed  in connection with this  protocol.  
Signature [CONTACT_138358]  [INVESTIGATOR_532705]  (Print)  
Name [CONTACT_532813]: [INVESTIGATOR_186978]. 
Return the original, completed  and signed to the Clinical Protocol & Data Management Office. 
Retain a copy in the regulatory binder. 
5 
 Table of Contents  
1. PROTOCOL  SYNOPSIS  ................................ ................................ ................................  11 
1.1. Trial Design Overview  ................................ ................................ ........................  12 
1.2. Trial Schema  ................................ ................................ ................................ ....... 13 
2. STUDY  OBJECTIVES  ................................ ................................ ................................ ... 14 
2.1. Primary Objective & Hypothesis  ................................ ................................ ........  14 
2.2. Secondary Objectives & Hypothesis  ................................ ................................ ... 14 
2.3. Exploratory Objectives & Hypothesis Objec tives:  ................................ .............  15 
3. BACKGROUND & RATIONALE  ................................ ................................ .................  [ADDRESS_691654] Population  ................................ ................................ ................  19 
3.8. Rationale for Dose Selection/Regimen/Modification  ................................ .........  19 
3.9. Rationale for Endpoints  ................................ ................................ .......................  19 
3.10.  Efficacy  Endpoints  ................................ ................................ ..............................  19 
3.11.  Safety Endpoints  ................................ ................................ ................................ . 19 
3.12.  Biom arker Research and Exploratory Endpoints  ................................ ................  20 
3.13.  Immunohistochemistry  ................................ ................................ ........................  20 
3.14.  Transcriptional Analyses  ................................ ................................ .....................  20 
3.15.  Proteomic analysis ................................ ................................ ...............................  20 
3.16.  Gene Analyses  ................................ ................................ ................................ ..... 21 
4. INVESTIGATIONAL AGENTS  ................................ ................................ ....................  21 
4.1. Pembrolizumab ................................ ................................ ................................ .... 21 
4.1.1  Preclini cal Data  ................................ ................................ ................................ ...............  22 
4.1.2  Clinical Data to  Date  ................................ ................................ ................................ ....... 23 
4.1.3  Rationale for Dose  Selection  ................................ ................................ ...........................  23 
4.2. Azacitidine (Vidaza)  ................................ ................................ ...........................  [ADDRESS_691655]-Treatment Visits  ................................ ................................ ..........................  33 
6.6.2  Follow -Up Visits  ................................ ................................ ................................ .............  33 
6.6.3  Survival  Follow -Up ................................ ................................ ................................ .........  33 
7. REGISTRATION PROCEDURES  ................................ ................................ .................  34 
7.1. CUMC Research Participant Registration ................................ ...........................  34 
CPDM Central Registration  Procedures:  ................................ ................................ ....................  34 
8. TREATMENT PLAN  ................................ ................................ ................................ ..... 35 
8.1. Agent  Administration  ................................ ................................ ..........................  35 
8.2. Dose Selection/Modification  ................................ ................................ ...............  36 
8.2.2  Dose Modification  (Escalation/Titration/Other)  ................................ .............................  36 
8.3. Pembrolizumab ................................ ................................ ................................ .... 37 
8.2.5  Acceptable Concomitant  Medications  ................................ ................................ .............  37 
8.2.6  Prohibited Concomitant  Medications  ................................ ................................ ..............  37 
8.2.7  Rescue  Medications  ................................ ................................ ................................ .........  38 
8.2.8  Supportive Care  Guidelines  ................................ ................................ .............................  38 
8.4. Azacitidine  ................................ ................................ ................................ ..........  53 
8.5. Diet/Activity/Other Considerations ................................ ................................ ..... 54 
8.2.10  Contraception  ................................ ................................ ................................ ..................  54 
8.2.11  Use in  Pregnancy  ................................ ................................ ................................ .............  55 
8.2.12  Use in  Nursing  ................................ ................................ ................................ .................  56 
8.6. Duration of Therapy  ................................ ................................ ............................  56 
8.7. Duration of Follow Up  ................................ ................................ ........................  56 
8.8. Criteria for Removal from Study  ................................ ................................ ........  56 
9. DOSING DELAYS/DOSE MODIFICATIONS  ................................ .............................  56 
9.1. Dose Modification for  Pembrolizumab  ................................ ...............................  56 
9.2 Dose Modification for  Azacitidine  ................................ ................................ ..................  58 
7 
 10. ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS  ..........................  58 
10.1.  Definition of an Overdose for this Protocol and Reporting of Overdose to  
Sponsor - Investigator and to  [COMPANY_006]  ................................ ................................ .... 58 
10.2.  Anticipated Adverse Events  ................................ ................................ ................  59 
10.3.  Adverse Events Definitions: ................................ ................................ ................  59 
10.2.2  Serious Adverse  Event:  ................................ ................................ ................................ ... 59 
10.2.3  Unanticipated  Problem:  ................................ ................................ ................................ ... [ADDRESS_691656]  ................................ ................................ ...................  60 
10.5.  Adverse Event Reporting Period  ................................ ................................ .........  61 
10.2.4  Baseline/Preexisting  Condition  ................................ ................................ .......................  [ADDRESS_691657]/Destruction/Returns and Reconciliation  ................................ ................  [ADDRESS_691658] Policies  ................................ ................................ ................................ . 67 
11.7.  Other Agent: Azacitidine  ................................ ................................ ....................  67 
12. STUDY CALENDAR  ................................ ................................ ................................ ..... 68 
12.1.  Trial Fl ow Chart  ................................ ................................ ................................ .. 68 
12.2.  Trial Procedures  ................................ ................................ ................................ .. 72 
12.3.  Administrative Procedures  ................................ ................................ ..................  72 
12.1.2  Inclusion/Exclusion  Criteria  ................................ ................................ ............................  72 
12.1.3  Medical  History  ................................ ................................ ................................ ...............  72 
8 
 12.1.4  Prior and Concomitant  Medications  ................................ ................................ ................  72 
[IP_ADDRESS]  Concomitant  Medications ................................ ................................ ....................  73 
12.1.5  Disease Details and  Treatments  ................................ ................................ ......................  73 
[IP_ADDRESS]  Prior Treatment  Details  ................................ ................................ .......................  73 
[IP_ADDRESS]  Subsequent Anti -Cancer Therapy  Status  ................................ .............................  73 
12.1.6  Clinical  Procedures/Assessments  ................................ ................................ ....................  73 
[IP_ADDRESS]  Physical  Exam  ................................ ................................ ................................ ..... 73 
[IP_ADDRESS]  Vital Signs  ................................ ................................ ................................ ...........  73 
[IP_ADDRESS]  Tum or Imaging and Assessment of  Disease  ................................ .......................  74 
[IP_ADDRESS]  Tumor Tissue Collection and Correlative Studies Blood  Sampling  ...................  74 
[IP_ADDRESS]  Laboratory  Procedures/Assessments  ................................ ................................ ... [ADDRESS_691659] – Solid  Tumors  ................................ ................................ ........  [ADDRESS_691660]  ................................ .....................  80 
13.6.  Analysis of Endpoints  ................................ ................................ .........................  80 
13.6.1  Efficacy  Endpoints  ................................ ................................ ................................ ..........  80 
13.6.2  Safety  Endpoints  ................................ ................................ ................................ .............  80 
13.6.3  Correlative  Endpoints  ................................ ................................ ................................ ...... 81 
[IP_ADDRESS]  Epi[INVESTIGATOR_532706]  ................................ ................................ .....................  81 
9 
 [IP_ADDRESS]  Immune  phenotypi[INVESTIGATOR_007]  ................................ ................................ ................................ ....... 82 
13.7.  Unblinding Procedures  ................................ ................................ ........................  82 
13.8.  Stoppi[INVESTIGATOR_1869]  ................................ ................................ ................................ .... 82 
14. DATA REPORTING / REGULATORY REQUIREMENTS  ................................ ........  83 
14.1.  Data Collection  ................................ ................................ ................................ .... 83 
14.2.  Data Reporting  ................................ ................................ ................................ .... 83 
14.3.  Data and Safety Monitoring Committee  ................................ .............................  83 
14.4.  Quality Control and Quality Assurance  ................................ ..............................  84 
14.5.  Confidentiality  ................................ ................................ ................................ ..... 85 
14.6.  Source Documents ................................ ................................ ...............................  85 
14.7.  Case Report Forms  ................................ ................................ ..............................  85 
14.8.  Reco rds Retention  ................................ ................................ ...............................  85 
15. STATISTICAL CONSIDERATIONS  ................................ ................................ ............  86 
15.1.  Statistical Analysis Plan  Summary  ................................ ................................ ...... 86 
15.2.  Populations for Statistical Analysis and Reporting  ................................ .............  86 
15.2.2  Safety  Population  ................................ ................................ ................................ ............  86 
15.2.3  Efficacy  Population  ................................ ................................ ................................ .........  86 
15.2.4  Reporting of  Outcomes  ................................ ................................ ................................ ... 87 
15.3.  Study Design/Endpoints  ................................ ................................ ......................  87 
15.2.6  Secondary  Endpoints  ................................ ................................ ................................ ....... 87 
15.2.6 .1 Definition of secondary  endpoints:  ................................ ................................ ..... 87 
▪ Duration of  Response  ................................ ................................ ................................ ...... 88 
▪ Disease Control  Rate ................................ ................................ ................................ ....... 88 
▪ Overall Survival  (OS)  ................................ ................................ ................................ ...... 88 
15.2.7  Exploratory and Ancillary  Studies  ................................ ................................ ..................  88 
15.4.  Size/Accrual Rate  ................................ ................................ ................................  [ADDRESS_691661] ................................ ................................ ...............................  89 
18. PUBLICATION PLAN  ................................ ................................ ................................ ... 90 
10 
 19. REFERENCES  ................................ ................................ ................................ ................  90 
20. APPENDICES  ................................ ................................ ................................ .................  95 
20.1.  Appendix 1 - ECOG Performance Status  ................................ .............................  95 
20.2.  Appendix 2 - Common Terminology Criteria for Adverse Events V4.0 (CTCAE)
 ................................ ................................ ................................ .............................  95 
20.3.  Appendix 3 - Response Evaluation Criteria in Solid Tumors (RECIST) 1.[ADDRESS_691662] Description - Pembrolizumab  ................................ ................................ . 66 
Table 9  Disease Assessment For Patients with Measurable Disease  ...............................  78 
11 
 1. PROTOCOL  SYNOPSIS  
This document is a protocol for a human research study. This study is to be conducted  
according to US and international standards of Good Clinical Practice (FDA Title 21 part 312  
and International Conference on Harmonization guidelines), applicable government 
regulations  and Columbia University Medical Center institutional research policies and  
procedures.  
 
Title  Phase II open -label, single -center study evaluating safety and efficacy  of 
pembrolizumab following induction with the hypomethylating  agent 
azacitidine in patients with locally advanced or metastatic  pancreatic 
cancer after failure of first -line therapy.  
Protocol  Number  AAAR3554  
Trial  Phase  2 
 
Methodology  This is a single arm, open -label phase II trial of combination  azacitidine 
and pembrolizumab in patients with locally advanced or  metastatic 
pancreatic cancer in order to evaluate safety and efficacy. The  primary 
endpoint is progression -free survival.  
 
Study  Duration  We estimate that the trial will require approximately 24 months  to 
complete, with up to 18 months accrual and an additional 6  months 
follow -up to evaluate the primary efficacy outcomes for all  subjects.  
Study  Center(s)  Columbia University Medical  Center  
 
 
 
 
 
Objectives  1. Primary objective: To evaluate the progression -free survival  per 
RECIST  1.1. 
2. Secondary  Objectives:  
a. Safety Objective: To determine the safety and  tolerability 
of induction therapy with azacitidine followed  by 
[CONTACT_532763].  
b. To evaluate the overall response rate (ORR), duration  of 
response (DOR), disease control rate (DCR), and time  to 
progression (TTP) per RECIST 1.1, and  OS. 
Number of  Subjects  [ADDRESS_691663], 
Dose,  Route, 
Regimen  • Pembrolizumab 200 mg IV every 3 weeks until  progression  
• Azacitidine 50 mg/m2 subcutaneous daily for 5 days every  28 
days 
 
12 
  
 
Duration of 
administration  Treatment will continue until progressive disease, unacceptable  adverse 
events, intercurrent illness that prevents further administration  of 
treatment, investigator’s decision to withdraw the subject,  subject 
withdrawal  of consen t, pregnancy  of the subject,  noncompliance  with 
trial treatment or procedure requirements, subject receives 35  treatments 
(approx. 2 years) of pembrolizumab, or administrative reasons  requiring 
cessation of  treatment.  
Reference  therapy  Not applicable – Single arm  study.  
 
 
Statistical 
Methodology  This is a single arm, phase II study. To detect an improvement  in 
progression free survival from a historical control of 2 months to  4 
months, with a one -sided p -value of 0.05 and 80% power, [ADDRESS_691664] -line chemotherapy, 5 -FU or  gemcitabine -based 
combination or monotherapy, prior to enrollment on the study. Azacitidine daily for 5 days  
will be given every 4 weeks (28 days). Fixed -dose pembrolizumab will be administered 
every  [ADDRESS_691665] 1.1 criteria; 
however, patients will be permitted to continue therapy following the development of 
progression of disease by  [CONTACT_393]  1.1 criteria if considered clinically appropriate by [CONTACT_532764].  
 
As preliminary data suggests there is minimal toxicity overlap between pembrolizumab and  a 
hypomethylating agent, there will be an accelerated Phase 1 dose determination component  
of the study. In the initial cohort, low -dose azacitidine will be administered, as studied in  
patients with advanced or metastatic solid tumors,1 and pembrolizumab will be administered 
at fixed  dose 
as detailed in the protocol. An initial cohort of 6 subjects will be enrolled, treated  with 
combination therapy, and assessed for safety. Following enrollmen t of the initial 6  
evaluable subjects all toxicity data will be reviewed. If 2 or more patients experience a 
treatment  related dose -limiting toxicity (DLT) within the first 6 weeks of treatment 
administration (Defined  in Sec tion 5.2 ), then accrual at that dose level will stop. We will 
allow for 1 dose reduction  in azacitidine and if agreed by [CONTACT_978], the study will resume at 
the lower dose (Dose -1) and  will again accrue 6 subjects who will receive combination 
therapy. If 2 or more subjects  experience treatment related DLTs at this level, we will 
discontinue the combination  study.  
13 
 If the combination dose is deemed safe (≤ 1 DLT), the study will complete accrual  with 
treatment of an additional 25 subjects at the safe combinati on dose. Adverse events will  be 
 
monitored throughout the trial and graded in severity according to the guidelines in the  NCI 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. DLT is defined as  a 
grade [ADDRESS_691666] (ECI) will be collected for  
[ADDRESS_691667] which patients may benefit from priming with  
hypomethylation followed by [CONTACT_4002] -1 inhibition. An exploratory objective is to evaluate changes  
in pharmacodynamics markers, including methylation  status.  
 
This study will be conducted in conformance with Good Clinical  Practices.  
 
Specific procedures to be performed during the trial, as well as their prescribed times  and 
associated visit windows, are outlined in the Trial Flow Chart – Section  12.1. 
 
1.2. Trial Schema  
[ADDRESS_691668] -line systemic  therapy.  
 
2.1. Primary Objective & Hypothesis  
 
Objective: To evaluate the progression -free survival (PFS) per RECIST  1.1. 
Hypothesis: We hypothesize that anti -tumor immunity can be achieved in  pancreatic 
adenocarcinoma and that combining hypomethylation with PD -1 blockade will alter  
gene signature [CONTACT_532814].  
 
2.2. Secondary Objectives & Hypothesis  
 
Safety and Tolerability Objective: To determine the safety and tolerability of  azacitidine 
combined with pembrolizumab in advanced pancreatic  cancer.  
Hypothesis: We hypothesize that azacitidine priming in conjunction with pembrolizumab  will 
 
be safe and tolerable and will delay progression of pancreatic  cancer.  
 
Efficacy Objective: To evaluate the overall res ponse rate (ORR), duration of response  (DOR), 
disease control rate (DCR) per RECIST 1.1, and overall survival  (OS).  

15 
 Hypothesis: We hypothesize that combination hypomethylation with PD -1 blockade  will 
enhance immune activation and lead to high response rates, longer periods of response,  
improve disease control, and prolonged survival compared to historical  controls.  
2.3. Exploratory Objectives & Hypothesis Objectives:  
▪ To explore the relationship between response rate and tumor -infiltrating lymphocytes  
and macrophage tumor infiltration within the tumor and the tumor microenvironment  
from pre - versus on -treatment  biopsies.  
▪ To evaluate the methylation status within tumor and peripheral  blood.  
▪ To identify molecular (genomic, m etabolic, and/or proteomic) determinants of  
response or resistance (e.g. PD -L1, gene expression profiling, or genomic variation), 
using  blood and/or tumor tissue to define novel predictive and pharmacodynamics 
biomarkers  and better understand the mechanism of action of  pembrolizumab.  
Hypothesis: We hypothesize that baseline markers of immune activation will correlate  with 
response to pembrolizumab and that responders to pembrolizumab will have distinct  tumor 
immune phenotype and gene expression pro filing compared to  non-responders.  
 
 
3. BACKGROUND & RATIONALE  
 
3.1. Pancreatic Cancer  Background  
 
Pancreatic ductal adenocarcinoma (PDA) has the worst prognosis of any major malignancy  in 
the [LOCATION_002] and, unlike other common cancers, annual deaths from PDA are rising.  
During the year 2014, it was estimated that 46,420 people would be diagnosed with PDA  and 
approximately 39,590 people would die in the U.S.2 Despi[INVESTIGATOR_103281],  cytotoxic 
chemotherapy for PDA has been disappointing with response rates of 20 -30% for the most  
active regimens3 and little activity for targeted therapi[INVESTIGATOR_014]. Even among the small subset of 
patient s who are suitable for surgical resection at the time of diagnosis, complete resection is 
followed  by [CONTACT_532765] >90% of patients without further systemic therapy, with a median 
time to recurrence of 6.[ADDRESS_691669] -line therapy. Consensus guidelines (such as the NCCN guidelines)  
recommend cli nical trial participation in this setting. The median progression -free and overall 
survival  for second -line therapy has been disappointing with a recent randomized cooperative 
group  study (SWOG S11156) resulting in a median P FS of [ADDRESS_691670] tumors are one of the body’s  
natural defense against the growth and proliferation of cancer cells. T cells play a critical role  
in antitumor immunity and their infiltration and activity have been linked to improved  
16 
 prognosis  
in a number of cancers.7,8 T-cells are activated when the T -cell receptor (TCR) recognizes  
tumor antigens bound to major histocompatibility complex proteins on antigen -presenting 
cells (APCs). This interaction leads to differentiation of T -cells into ant itumor effectors that 
are capable  of destroying cancer cells expressing the cognate antigen. An additional 
costimulatory signal is  also necessary for T -cell activation, which is provided by [CONTACT_532766]28 (on the  T- cell) and B7 proteins (CD8 0 or CD86 on APCs). Once 
activated, T -cells upregulate  inhibitory (checkpoint) molecules, which attenuate and 
eventually terminate the T -cell response. Over  time 
and under pressure from immune attack, cancers develop strategies to evade  immune -
mediated kil ling allowing them to develop unchecked. Immune evasion can occur via a wide 
range  of mechanisms and is now recognized as one of the hallmarks of cancer. One such  
mechanism involves exploitation of immune checkpoint molecules to suppress anti -tumor T -
cell activity.  
 
Programmed cell death ligand 1 (PD -L1) is another checkpoint protein and is upregulated in  
a broad range of cancers with a high frequency – up to 88% expression in some tumor types. 
In a number of these cancers, including lung,[ADDRESS_691671]-line chemotherapy.26- 30 Pembrolizumab is also approved in NSCLC for two other 
indications: as first -line treatment for metastatic NSCLC with express ion of PD -L1 on at 
least 50% of tumor cells, and to be  used with pemetrexed and carboplatin for patients with 
previously untreated advanced  nonsquamous NSCLC regardless of whether their tumors 
express PD -L11 (Langer CJ et al. Lancet  Oncol.  
2016; 17(11):149 7-1508). Additionally, pembrolizumab is approved for recurrent or  
metastatic head and neck squamous cell carcinoma (HNSCC) after platinum -based  
chemotherapy regardless of PD -L1 staining. Recently, pembrolizumab was FDA -approved 
for patients  with solid tumors that were mismatch repair deficient and microsatellite unstable   
 
Despi[INVESTIGATOR_532707], treatment  of 
patients with pancreatic cancer with these single agents has been ineffective. One  difference 
[ADDRESS_691672] responded to checkpoint inhibitors and pancreatic cancer is the  
immune status of the tumor microenvironment. 32 Cancers that respond to checkpoint 
inhibitors tend to  be naturally infiltrated wit h effector lymphocytes while pancreatic cancer is 
characterized by a  highly  
immunosuppressive tumor microenvironment composed of multiple  immunosuppressive 
regulatory  cells.  
 
3.3. Epi[INVESTIGATOR_532708] (GI) cancers possess high degrees of epi[INVESTIGATOR_532709].  Epi[INVESTIGATOR_532710], such as DNA methylation, in tumor cells control gene expression and are known  to 
alter immune cell phenotype and function.  Methylation of cytosine residues, at CpG sites  
that are unmethylated in normal tissue, is catalyzed by [CONTACT_532767] 
(DNMTs) .33,[ADDRESS_691673] very early during the histopathological development of this neoplasia. The loss of  
p16 expression in pancreatic intraepi[INVESTIGATOR_28601] (PanIN) le sions has been reported in  
patients with chronic pancreatitis38, suggesting that this modification may contribute to the  
predisposition of patients affected by [CONTACT_532768]. 
DNA fro m 65 PanIN lesions was assessed for methylation status of 8 genes previously 
recognized to  be abnormally hypermethylated in invasive pancreatic adenocarcinoma.39 
Methylation at any one  of these genes was identified in 68%. Ad ditionally, aberrant CpG 
island hypermethylation  was observed at early stages of PanINs and the incidence 
progressively increased during  neoplastic development.  
 
Epi[INVESTIGATOR_532711] -expression of silenced genes induces chemosensitization, and  the 
use of epi[INVESTIGATOR_532712]. A recent  
study showed that after treatment with low -dose [ADDRESS_691674], ovarian, and 
colorectal  cell line lines as well as primary tumors, 20% of all upregulated gene  sets 
belonged  to immunomodulatory pathways (e.g. interferon signaling, cytokines, antigen  
presentation, inflammation, and cancer testes antigens, and the commonly upregulated gene 
sets between the  3 cancer types.40 In murine  mouse model, checkpoint inhibition combined 
with 5 -azacitidine  and entinostat resulted in a striking improvement in mouse survival and 
tumor growth inhibition  with complete eradication of large colon  cancers.41 
 
An important  feature of pancreatic cancer is its low cellularity and surrounding  desmoplastic 
reaction, highlighting the importance of the tumor microenvironment in the initiation  and 
progression of pancreatic cancer. In one study, the use of hypomethylating agents  
successfully inhibited tumor progression in a stroma -rich mouse model of pancreatic  cancer.  
 
18 
 In summary, a novel approach to improve response rates with immune checkpoint blockade  
is the use of epi[INVESTIGATOR_532713] “prime” the tumor and its microenvironme nt. Expression  
of critical immune -related genes can be restored with hypomethylating agents (HMAs),  
impairing tumor growth through a variety of  mechanisms.  
 
3.4. Rationale  
 
3.5. Rationale for Combining Hypomethylating Agents with Immunotherapy  
Cancer testis antigens  (CTAs) are protein fragments that are derived from proteins normally  
only expressed during embryonic development or in immune privileged organs such as the 
testes  and brain. Because they are not typi[INVESTIGATOR_532714], they are recognized as foreign the human immune system and are able to 
stimulate  an immune response.[ADDRESS_691675] also been found to silence antigen -presenting 
machinery genes  and downregulate MHC class I expression on tumor cells.44 Treatment with 
agents such  as azacitidine (a DNMT inhibitor) has reversed this phenotype in various in vitro 
and in vivo models.[ADDRESS_691676] confirmed that 
treatment  with HMAs is followed by [CONTACT_532769] -1/PD -L1 signaling.52 A recent 
study used  an animal metastatic cancer model that is known to be resistant to treatment with  
immune checkpoint blockade. HMAs and histone deacetylating agents  were successfully 
used to  reverse this resistance, presumably by [CONTACT_532770] 
(MDSCs) within  the tumor  microenvironment .41 
 
In summary, given that epi[INVESTIGATOR_532715], there is strong pre -clinical  and 
clinical rationale to investigate the combination of induction with a hypomethylating  agent 
followed by [CONTACT_299621]. In this trial, subjects will be treated with azacitidine,  a 
DNMT inhibitor, and pembrolizumab in a sequential  fashion.  
 
3.6. Rationale for the Combination in Pancreatic Cancer  
Our pre -clinical data suggests that decitabine treatment in the KPC model of pancreatic  cance r 
leads to a significant upregulation of interferon -related genes and a polarization of the  
infiltrating immune cells.53  We identified a shift towards a favorable macrophage phenotype 
19 
 (M1 vs  M2) and an increase in tumor infi ltrating CD8 T cells. Based on these results we have 
evaluated  the effect of single agent decitabine or anti -PD1H (a homologue of PD1 with very 
similar  function and expression pattern) compared to combination therapy (treatment with 
decitabine followed  by [CONTACT_4002]1 blockade). Our preliminary results showed minimal effect of 
either agent alone on  tumor growth but marked decrease in tumor progression in the 
combination arm. These results form  the foundation of this phase II  study.  
 
This study will treat patients with a combination of azacitidine and pembrolizumab. A  direct 
comparison of azacitidine and decitabine, in terms of efficacy within a controlled clinical  trial, 
has not been performed thus far. In randomized MDS trials, the remission rates were si milar  
for azacitidine and decitabine but the overall survival in the experimental arm was  
significantly shorter in the decitabine trial compared to the azacitidine trial.54,55 A primary 
reason t o utilize azacitidine in this setting is our desire to utilize reduced dose therapy with the 
goal of maintaining subjects on therapy for as long as tolerated. Low -dose azacitidine is being 
tested  in phase I/II clinical trials for advanced solid tumors —main ly colorectal cancer, small -
cell lung carcinomas, ovarian cancer, and breast cancer. Furthermore, low -dose azacitidine 
with the HDAC inhibitor etinostat in refractory advanced non -small cell lung cancer was  well-
tolerated and led to impressive results in a  subset of  patients.[ADDRESS_691677]  line 
chemotherapy. Current guidelines and clinical practice recommend clinical trial as a  preferred 
option for this patient population. This study will enroll eligible patients in the  second -line 
setting irrespective of PD -L1 status, however, this will be checked in the baseline  tumor 
specimens.  
 
3.8. Rationale for Dose Selection/Regimen/Modification  
Low-dose azactidine, as used in conjunction with cytotoxic chemotherapy for solid tumors,  
will be given in combination with fixed dose pembrolizumab as  detailed in Section  4.1.[ADDRESS_691678] notably overall response rate and overall  
survival.  
 
3.11. Safety Endpoints  
The primary  safety  objective  of this trial is to characterize  the safety  and to lerability  of 
pembrolizumab in combination with azacitidine in subjects with locally -advanced or  
metastatic pancreatic cancer. The primary safety analysis will be based on subjects who  
experienced toxicities as defined by [CONTACT_3989] (Appendix 2). Safety will be  assessed by 
[CONTACT_532771] 
20 
 drug,  including serious adverse events (SAEs) and events of clinical interest  (ECIs).  
 
Safety will be assessed by [CONTACT_532772], Version 4.0. The attribution  to 
drug, time -of-onset, duration of the event, its resolution, and any concomitant  medications 
administered will be recorded. Adverse events will be analyzed including but not limited to  all 
adverse events (AE), SAEs, fatal AEs , and laboratory changes. Furthermore, specific events  of 
clinical interest will be collected as described in Section  10.4. 
 
3.12. Biomarker Research and Exploratory Endpoints  
Additional biomarker research to identify factors important for azacitidine and  pembrolizumab  
 
therapy may also be pursued. For example, tumor and blood samples (including serum  and 
plasma) from this study may undergo proteomic, genom ic, metabolomics, and  transcriptional 
analyses. This research may evaluate factors important for predicting responsiveness  or 
resistance to azacitidine and pembrolizumab therapy and other immunologic  targets.  
 
Both blood and tissue samples will be collecte d as available for these assays and patients will  
be asked to consent to use of any medically extra samples. Assays may include but are not  be 
limited to the  following:  
 
3.13. Immunohistochemistry  
PD-L1 expression in tumor tissue will be characterized by [CONTACT_532773] -L1 expression and response to treatment with pembrolizumab 
(this is  a secondary objective of the trial). Other exploratory biomarkers (e.g. PD -1 expression, 
markers  of T-cell phenotype) may also be  evaluated.  
 
3.14. Transcriptional Analyses  
As an exploratory analysis, messenger RNA (mRNA) expression profiling in archival  material 
(biopsy specimens, peripheral blood) will be completed to assess expression of  approximately 
[ADDRESS_691679]  an 
inflamed/ immune phenotype based on gene expression signatures capturing PD -L1 &  
interferon gamma transc riptional programs. Global profiling will also be pursued. Expression 
of individual genes related to the immune system may also be evaluated such as immune 
signatures  and critical cytokines (e.g., IL -10). MicroRNA profiling may also be pursued in 
serum  samples. 
 
3.15. Proteomic analysis  
In addition to expression on the tumor tissue, PD -L1 can be shed from tumor and released  into 
the blood. Enzyme -linked immunoassay can measure PD -L1 in serum and correlate  this 
expression with response to pembrolizumab therapy, as well as levels of PD -L1 IHC or protein  
in the tumor. Blood would be a less invasive component from which to measure PDL1  protein 
biomarker. In addition to this specific protein biomarker, both tissue and blood derivatives can  
be subjected to proteomic profiling studies using a variety of platforms that could include but  
are not limited to immunoassay, Liquid Chromatography/Mass Spectrometry. This approach  
could identify novel protein biomarker that could aid in subject selection fo r pembrolizumab  
21 
 therapy.  
 
3.16. Gene Analyses  
The application of new technologies, such as next generation sequencing, has provided  
scientists the opportunity to define certain tumor types at the genetic level as being 
‘hypermutated’ or  can detect the presence o f specific T -cell clones within the tumor 
microenvironment or in  the peripheral blood. There is a potential that the hypermutated state 
and/or increased  T-cell clonality may correlate with response to pembrolizumab therapy, 
and/or that the  converse, ‘hypomutated’ state or lack of dominant T -cell clones may correlate 
with non-response.  
 
In addition, understanding genetic determinants of drug response is an important  endeavor 
during medical research. This research will evaluate whether genetic variation  within a  clinical 
trial population correlates with response to the treatment(s) under evaluation. If genetic  
variations  found to predict efficacy or adverse events, the data might inform optimal use of 
therapi[INVESTIGATOR_532716].  
 
 
4. INVESTIGATIONA L AGENTS  
 
4.1. Pembrolizumab  
 
Pembrolizumab (MK -3475) is a potent and highly selective humanized monoclonal  
antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction 
between PD  -1 and its ligands, programmed death ligand 1 (PD-L1) and programmed 
death ligand  2 
(PD-L2). KEYTRUDA® (pembrolizumab) has recently been approved in the United  States 
for the treatment of patients with unresectable or metastatic melanoma and disease  
progression following treatment with ipi[INVESTIGATOR_90913] a  BRAF inhibitor, if BRAF V600  
mutation -positive. Pembrolizumab was also recently approved for the treatment of patients 
with metastatic  non- small cell lung cancer (NSCLC) whose tumors express PD -L1 as 
determined by a Food  and Drug Administration (FDA) -approved test, with disease 
progression on or after  platinum - containing  chemotherapy.  
The importance of intact immune surveillance in controlling outgrowth of  neoplastic 
transformation  has been  known  for decades57. Accumulating  evidence  shows  a correlation  
between tumor -infiltrating lymphocytes (TILs) in cancer tissue and favorable prognosis in  
various malignancies58-61. In particular,  the presence  of CD8+  T-cells and the ratio of CD8+  
effector  T- cells / FoxP3+  regulatory  T-cells seems  to correlate  with improved  prognosis  
and long-term survival in many solid  tumors.  
 
The PD -[ADDRESS_691680] hijacked by [CONTACT_532774]. The normal function of PD -1, expressed on the cell surface of activated T -
cells under healthy conditions, is to down -modulate unwanted or excessive immune responses,  
including autoimmune reactions. PD -1 (encoded by [CONTACT_13228]1) is an Ig superfamily 
22 
 member  related to CD28 and CTLA -4 which has been shown to negatively regulate antigen 
receptor  signaling upon engagement of its ligands (PD -L1 and/or  PD-L2)62. 
 
The structure of murine PD -1 has been identified. PD -1 and family members are type  I 
transmembrane glycoproteins containing an Ig Variable -type (V -type) domain responsible  for 
ligand binding and a cytoplasmic tail which is responsible for the binding of signaling  
molecules. The cytoplasmic tail of PD -1 contains 2 tyrosin e-based signaling motifs, an  
immunoreceptor tyrosine -based inhibition motif (ITIM), and an immunoreceptor tyrosine 
based switch  motif (ITSM).  
 
Following T -cell stimulation, PD -[ADDRESS_691681] from, t hat of CTLA -4 as both molecules regulate an overlappi[INVESTIGATOR_532717]. PD -1 was shown to be expressed on activated lymphocytes including peripheral  CD4+ 
and CD8+ T -cells, B -cells, T -regulatory cells and natural killer cells63. Expression has also  been  
shown during thymic development on CD4 –/CD8 – (double negative) T -cells as well as  subsets  
of macrophages and dendritic  cells.  
 
The ligands for PD -1 (PD -L1 and PD -L2) are constitutively expressed or can be induced in  a 
variety of cell types, including non -hematopoietic tissues as well as in various tumors64-66. Both 
ligands are type I transmembrane receptors containing both IgV - and IgC -like domains in  the 
extracellular region and contain short cytoplasmic regions with no known signaling  motifs.  
Binding of either PD -1 ligand (PD -L1 or PD -L2) to PD -[ADDRESS_691682] notably on vascular endothelium, whereas PD -L2 protein is only  detectably 
expressed on antigen -presenting cells found in lymphoid tissue or chronic  inflammatory 
environments. PD -L2 is thought to control immune T -cell activation in lymphoid  organs, 
whereas PD -L1 serves to dampen unwarranted T -cell function in peripheral tissues.  Although 
healthy organs express little (if any) PD -L1, a variety of cancers were demonstrated to  express 
abundant levels of this T -cell inhibitor. PD -1 has b een suggested to regulate tumor -specific  T- 
cell expansion in subjects with melanoma. This suggests that the PD -1/PD -L1 pathway plays  a 
critical role in tumor immune evasion and should be considered as an attractive target  for 
therapeutic  intervention.  
 
4.1.[ADDRESS_691683] shown that the administration of  antibodies 
blocking the PD -1/PD -L1 interaction enhances infiltration of tumor -specific CD8+  T-cells 
and leads ultimately to tumor rejection, either as a monotherapy or  in combination with  other 
treatment modalities. Anti -mouse PD -[ADDRESS_691684]  effectively 
promotes CD8+ T -cell infiltration into the tumor and the presence of IFN -ɣ, granzyme B  and 
perforin, indicating that the mechanism of action involved local infiltration and activation  of 
[ADDRESS_691685] confirmed the in vivo efficacy of  PD-
1 blockade as a monotherapy as well as in combination with chemotherapy in syngeneic  
mouse tumor models (see the Investigator Brochure for additional  details).  
 
4.1.[ADDRESS_691686] demonstrated efficacy using pembrolizumab in subjects with  advanced 
melanoma, non -small cell lung cancer (NSCLC), head and neck cancer, bladder  cancer, 
Hodgkin’s lymphoma, triple -negative  breast cancer, and gastric adenocarcinoma. In addition, 
recent data demonstrate emerging evidence of single -agent activity in additional tumor  types 
such as mesothelioma, urothelial cancer, ovarian cancer, neuroendocrine carcinoma, and  small 
cell lung  cancer. 
 
4.1.3 Rationale for Dose  Selection  
The dose of pembrolizumab planned to be studied in this trial is 200 mg Q3W. Information  on 
the rationale for selecting the 200 mg Q3W dose is summarized  below.  
 
Keynote -001, an open -label Phase I study, was conducted to evaluate the safety,  tolerability, 
pharmacokinetics (PK) and pharmacodynamics, and anti -tumor activity of single  agent 
pembrolizumab. The dose escalation portion of this trial evaluated three dose levels, 1 mg/kg,  
3 mg/kg and 10 mg/kg, adminis tered every 2 weeks (Q2W) and dose expansion cohorts  
evaluated 2 mg/kg Q3W and 10 mg/kg Q3W in subjects with advanced solid tumors. All dose 
levels  were well tolerated and no dose -limiting toxicities were observed. This first -in- human 
study  of pembrolizum ab showed evidence of target engagement and objective evidence of 
tumor  size reduction at all dose levels. No maximum tolerated dose (MTD) has been 
identified. In  addition, two randomized cohort evaluations of melanoma subjects receiving 
pembrolizumab at a  dose of 2 mg/kg versus 10 mg/kg Q3W have been completed, and one 
randomized cohort evaluating  10 mg/kg Q3W versus 10 mg/kg Q2W has also been completed. 
The clinical efficacy and  safety data demonstrate a lack of important differences in the 
efficacy and s afety profiles across  doses.  
 
An integrated body of evidence, based on dose/exposure efficacy and safety  relationships, 
demonstrated no clinically significant differences in efficacy and safety between doses of  200 
mg or 2 mg/kg Q3W in patients with melanoma and NSCLC. As such, the recommended  fixed 
dose is 200 mg  Q3W.  
 
The pharmacokinetics (PK) of pembrolizumab was characterized using a population PK  
analysis with concentration data collected from 2841 patients with various cancers who  
received pembr olizumab doses of 1 to 10 mg/kg Q2W or 2 to 10 mg/kg Q3W. The PK profile  
of pembrolizumab was consistent with that of other humanized monoclonal antibodies,  which 
typi[INVESTIGATOR_44769] a low clearance and a limited volume of distribution. The distribution  of 
expo sures from the 200 mg fixed dose overlapped with the 2 mg/kg dose and,  importantly, 
maintained individual patient exposures within the exposure range established in melanoma  
and NSCLC associated with maximal clinical response. Pharmacokinetic properties  of 
pembrolizumab, and specifically the weight -dependency in clearance and volume of  
distribution, were consistent with no meaningful advantage to weight -based dosing relative to 
fixed  dosing.  
[ADDRESS_691687] interaction with tumor cells, rendering it 
independent  of the specific tumor type. In addition, available PK results in subjects with 
melanoma,  NSCLC, and other tumor types support a lack of meaningful difference in 
pharmacokinetic  exposures obtained at tested doses among tumor types. Thus, the 200 mg 
Q3W fixed -dose regimen is  now considere d an appropriate fixed dose for other tumor 
indications as  well.  
 
4.2. Azacitidine (Vidaza)  
 
Azacitidine is a pyrimidine nucleoside analog of cytdidine. It is a metabolic inhibitor  that 
promotes hypomethylation of DNA and restores normal gene differentiation an d proliferation. 
Azacitidine is also directly cytotoxic to rapi[INVESTIGATOR_532718]. Hypomethylation may promote epi[INVESTIGATOR_532719], improving the tumor microenvironment, an d enhancing  gamma 
interferon  sensitivity40,50,69,70. 
 
Despi[INVESTIGATOR_532720], single  
agent results in solid tumors have been disappointing. One of the historical reasons for this has  
been the use of cytotoxic doses which led to significant toxicity.[ADDRESS_691688] shown a  significantly increased efficacy of azacitidine plus anti -CTLA -4 
therapy compared to anti -CTLA -4 therapy alone in a murine melanoma  model.  
 
The pharmacokinetics of azacitidine were studied in 6 myelodysplastic (MDS) patients  
following a single 75 mg/m2 SubQ dose and a single 75 mg/m2 IV dose. Azacitidine is rapi[INVESTIGATOR_532721], and the bioavailability of SubQ azacitidine relative to IV 
azacitidine was approximately 89% based on area under the curve. It is FDA -approved for IV 
or SubQ administration in  MDS.  
 
Azacitidine for subcutaneous injection is supplied as a lyophilized powder in [ADDRESS_691689] the diluent slowly into the vi al. 
Vigorously shake or roll the vial until a uniform suspension is achieved. The suspension will 
be cloudy  and should not be filtered after reconstituting since doing so could remove the active 
substance.  The resulting suspension will contain azacitidine 25 mg/mL.  
 
For immediate SubQ administration, doses greater than [ADDRESS_691690] may be held under refrigerated conditions (2
 C - 8
C , 36
 F - 46
F) 
for up to 8 hours. When azacitidine is reconstituted using refrigerated (2
 C - 8
C , 36
 F - 
46
F) water for injection, the  reconstituted product may be stored under refrigerated 
conditions (2
 C - 8
C , 
 
36
F - 46
F) for up to [ADDRESS_691691] 
be re-suspended immediately prior to  administration.  
 
Doses greater than 4 mL should be divided equally into 2 syringes and injected into 2  separate 
sites. Rotate sites for each injection (thigh, abdomen, or upper arm). New injections should  be 
given at least one inch from an old site and never into areas where the site is tender, bruised,  
red, or hard. The recommended starting dose in MDS is 75 mg/m2 SubQ, however,  lower doses  
have been shown to be effective in solid tumor patients in conjunction with other  
chemotherapeutic agents. In this protocol, we will utilize lower starting dose of azacitidine (50 
mg/m2 ) in conjunction with  pembrolizumab.  
 
 
5. STUDY DESIGN  
 
5.1. General  Design  
 
This is a single -arm, open -label, single site Phase II trial of azacitidine combined  with 
pembrolizumab in previously systemically treated subjects with a histologically or  
cytologically confirmed diagnosis of pancreatic ductal adenocarcino ma. Pre -treatment biopsies 
will be required for those subjects without an archival sample. All subjects will be required to 
provide  a tumor tissue sample, either from the primary or a metastatic site, for biomarker 
analysis after  8 weeks on treatment. Thir ty-one evaluable subjects will be allocated to receive 
azacitidine  50 mg/m2 SubQ for 5 days every 28 days (Q4W) with single -agent pembrolizumab 
200 mg  IV every 3 weeks (Q3W) beginning on week  3. 
 
The primary objective of this trial is to determine the PFS of pembrolizumab given  in 
combination with a hypomethylating agent. Beginning with screening, all imaging  assessments 
will be evaluated using RECIST 1.1. On -study imaging assessments will be performed every  8 
26 
 weeks (Q8W) calculated from the date of all ocation and independent of treatment  delays.  
RECIST 1.[ADDRESS_691692] radiologic evidence  
of progressive disease  (PD).  
 
Following the first radiologic evidence of PD by [CONTACT_393] 1.1, treatment decisions may be  
made  by [CONTACT_180703] 1.[ADDRESS_691693] (irRECIST) to accommodate the tumor response patterns seen with pembrolizumab  
treatment (e.g.,  tumor  flare).  This was first described  by [CONTACT_180704],  et al. [ADDRESS_691694] is a chieving a  clinically meaningful benefit; an exception for continued treatment may 
be considered  following consultation with the  PI. 
 
Subjects may continue to be treated with pembrolizumab until PD is confirmed  by 
[CONTACT_393] 1.1, unacceptable adverse events (A Es), intercurrent illness that prevents  further  
administration of treatment, investigator’s decision to withdraw the subject,  subject 
withdrawal of consent, pregnancy of the subject, noncompliance with trial treatment  or 
procedure requirements, administrat ive reasons, or the subject has received 35  trial 
treatments (approximately 2 years) with pembrolizumab. Subjects who discontinue  trial 
treatment for a reason other than disease progression will move into the Follow -Up Phase  
and should be assessed every 8 weeks (±7 days) by [CONTACT_532775].  
 
Disease status will continue to be monitored until whichever of the following  occurs 
first: the start of new anti -cancer treatment, disease progression, death, or the end of  
the study. All subjects will be followed by [CONTACT_532776] 12 weeks (+/ - 2 
weeks) for  overall survival (OS) until death, withdrawal of consent from participation 
in the study, or the end of  the study, whichever comes  first. 
 
Subjects who attain a CR by [ADDRESS_691695] 8 treatments (approximately 6 months of therapy) with  
pembrolizumab may discontinue treatment at the discretion of the investigator after 
receiving at least  2 treatments beyond the in itial determination of a CR. Subjects who stop 
pembrolizumab  after receiving 35 trial treatments (approx. 2 years) for reasons other than 
PD or intolerability  or who stop after attaining a CR may be eligible for retreatment with up 
to an additional  17 trea tments (second course of treatment, approximately 1 year) after they 
have  experienced  radiographic PD after consultation with the principal investigator. The 
decision to retreat will  be at the discretion of the investigator only if no other cancer 
treatmen t was administered since  the last dose of pembrolizumab, the subject still meets the 
parameters listed in the inclusion  and exclusion criteria, and the trial remains  open.  
 
Adverse events will be monitored throughout the trial and graded in severity according to  
27 
 the guidelines outlined in the National Cancer Institute (NCI) Common Terminology 
Criteria  for Adverse Events (CTCAE) version 4.0 ( Appendix 2 ). After the end of treatment,  
each subject will be followed f or 30 days for AE monitoring. Serious adverse events (SAEs)  
will be collected for [ADDRESS_691696] initiates new anticancer therapy, whichever is  earlier.  
 
This study will be conducted in conformance with Good Clinical Practices  (GCP).  
 
Specific procedures to be performed during the trial, as well as their prescribed times  and 
associated visit windows, are outlined in the Trial Flow Chart - Section 12.1. Details of  each 
procedure are provided in Section 12.2 – Trial  Procedures . 
 
5.2. Dose Limiting Toxicities  
 
All toxicities will be graded according to the NCI CTCAE version 4.0 and assessed  for 
relationship to study  medications.  
 
The incidence of DLT(s) assessed in the first [ADDRESS_691697] 1 dose of pembrolizumab  
after receiving the initial week of azacitidine. DLT should not be an AE considered by [CONTACT_532777]. The following drug -related AE (whet her related to one or 
both agents)  will be considered a  DLT:  
 
• Any Grade ≥ [ADDRESS_691698] has baseline Grade ≤ [ADDRESS_691699], ALT, or total bilirubin, a drug -related  Grade  
≥ [ADDRESS_691700] and/or ALT > 2x baseline or  
a maximum of > 8x ULN that does not resolve to Grade 2 or less within 48 hours  
(if symptomatic) or that does not resolve to Grade 1 or less within 3 weeks of onset  
(if asymptomatic) will be considered a  DLT.  
 
• Any Grade ≥ 3 drug -related non -hematological laboratory abnormality with  
the following  exceptions:  
- Grade 3 abnormal laboratory result that is asymptomatic and lasts no longer than  
72 hours.  
- Grade 4 lymphocytopenia not associated with symptoms or clinical  
manifestations  
 
• Any toxicity managed by [CONTACT_532778] (see section  9.1). 
• Any toxicity managed by [CONTACT_532779] (see section  9.2). 
• Grade ≥ 3 thrombocytopenia with bleeding, and febrile neutropenia of any  Grade.  
28 
  
5.3. Number of Patients  
Thirty -one subjects who are evaluable for progression -free survival will be  enrolled. 
Unevaluable patients (as defined in Section 13.1.1 ) will be  replaced.  
 
 
6. SUBJECT SELECTION AND WITHDRAWAL  
 
Male and female subjects with advanced pancreatic ductal adenocarcinoma after progression  
on first -line systemic therapy who are considered incurable will be enrolled in this  trial. 
 
6.1. Inclusion Criteria  
In order to be eligible for participation in this trial, the su bject  must:  
1. Be willing and able to provide written informed consent for the  trial. In cases of partial 
impairment, impairment that fluctuates over time, or complete impairment due to dementia, 
stroke, traumatic brain injury, developmental disorders (includ ing mentally disabled 
persons), serious mental illness, and delirium, a subject may be enrolled if the subject’s 
legally authorized representative consents on the subject’s behalf.  
▪ Age ≥18 years of age on day of signing informed  consent.  
▪ Have histologically or cytologically confirmed diagnosis of pancreatic  
ductal adenocarcinoma  
▪ Have a predicted life expectancy of greater than 3  months.  
▪ Have measurable disease based on RECIST  1.1. 
▪ Have a performance status of [ADDRESS_691701] dose of study  drug.  
▪ Have documented radiographic progression to or documented intolerance of first  line 
systemic chemotherapy which included at least gemcitabine or 5 -FU based  regimen 
(including  capecitabine).  
▪ Subjects who have documented disease recurrence within [ADDRESS_691702] not received an additional line of systemic therapy . Subjects who 
recur greater than 6 m onths after completing adjuvant or  neoadjuvant chemotherapy 
will not be eligible unless they receive additional chemotherapy  for advanced  disease.  
 
▪ Have a negative urine or serum pregnancy test within [ADDRESS_691703] dose of study medication (Cycle 1, Day 1) (female subjects of 
childbearing potential).  If the urine test is positive or cannot be confirmed as 
negative, a serum pregnancy test  will be  required.  
• Be willing to use an adequate method of contraception for the course of the study  
through [ADDRESS_691704] dose of study medication (male and female subjects  
of childbearing potential [see Section  8.5.2 ]). 
29 
 • Demonstrate adequate organ function as defined in Table 1.  
 
Table 1. Adequate Organ Function Laboratory Values  
 
 
 
6.2. Exclusion Criteria  
The subject must be excluded from participating in the trial if the  subject:  
▪ Is currently participating and receiving study therapy or has participated in a 
study of  an investigational agent and received study therapy, or 
herbal/complementary oral or  IV medicine within [ADDRESS_691705]  dose of  
treatment.  
▪ All toxicities attributed to prior anti -cancer therapy other than alopecia and 
fatigue  must have resolved to Grade 1 (NCI -CTCAE Version 4.0) or baseline 
prior to  administration of first dose of study drug. Subjects with toxicities 
attributed to prior anti -cancer  therapy that are not expected to resolve and result 
in long -lasting sequelae, such as  chronic neuropathy after platinum based 
therapy, are permitted to  enroll  
▪ Has received chemotherapy or radiotherapy within [ADDRESS_691706] dose of  
study medication.  
▪ Had a solid organ or hematologic  transplant.  System Laboratory Value 
Hematological  
Leukocytes ≥2,000/mcL 
Absolute neutrophil count (ANC)  ≥1,500 /mcL 
Platelets  ≥100,000 / mcL 
Hemoglobin ≥9 g/dL without transfusion or EPO dependency within 7 days 
Renal  
Creatinine OR 
Meas ured or calculateda  creatinine clearance 
(GFR  can also be used in place of creatinine or CrCl) ≤1.5 X upper limit of normal (ULN) OR 
≥60 mL/min for subject with creatinine levels > 1.[ADDRESS_691707] 
Hepatic  
 
Total bilirubin ≤ 2 mg/dL or direct bilirubin ≤ ULN for those with total 
bilirubin >2xULN 
Subjects with Gilbert Syndrome will be eligible if total bilirubin 
is < 3.0 mg/dL. 
AST (SGOT)  and ALT (SGP T) ≤ 2.[ADDRESS_691708] OR 
≤ [ADDRESS_691709] for subjects with liver metastases 
Albumin >3.0 mg/dL 
 
Amylase and Lipase  ≤1.[ADDRESS_691710]. Subjects with Amylase or Lipase  > 1.[ADDRESS_691711] may 
enroll if there are neither clinical nor radiographic signs of 
pancreatitis 
Coagulation  
INR or PT 
aPTT  ≤1.[ADDRESS_691712] is recei ving anticoagulant therapy 
as long as PT or aPTT is within therapeutic range of intended 
use of anticoagulants 
 
30 
 ▪ Has experienced weight loss >10% over [ADDRESS_691713] dose of study  therapy.  
▪ Has active autoimmune disease that has required systemic treatment in past 2 years  
(i.e. with use of disease -modifying agents, corticosteroids, or immunosuppressive  
drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid  
replacement therapy for adrenal or pi[INVESTIGATOR_13002], etc.) is not considered a 
form of  systemic tr eatment.  
▪ Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at a  
dose greater than 10mg/day of Prednisone equivalent) or any other form  of 
immunosuppressive therapy within [ADDRESS_691714] dose of trial  treatment.  
▪ Has a  diagnosed additional malignancy within [ADDRESS_691715] cancers. 
Subjects wi th another malignancy diagnosed >[ADDRESS_691716] dose of trial 
medication who  were treated with curative intent and are not undergoing active 
therapy will be  eligible.  
▪ Has a known history of, or any evidence of, interstitial lung disease or acti ve 
non- infectious  pneumonitis.  
▪ Has an active infection requiring systemic  therapy.  
▪ Has clinically relevant ascites at baseline (defined as requiring paracentesis) or  
with moderate radiographic ascites. A minimal amount of radiographic ascites is  
allowed.  
▪ Has a history of current evidence of any condition, therapy, or laboratory  
abnormality that might confound the results of the trial, interfere with the subject’s 
participation  for the full duration of the trial, or is not in the best interest of the 
subje ct to participate,  in the opi[INVESTIGATOR_80021], including  dialysis.  
▪ Has known psychiatric or substance abuse disorders that would interfere with  
cooperation with the requirements of the  trial. 
▪ Is pregnant or breastfeeding, or expecting to conceive or father children within  the 
projected duration of the trial, starting with the screening visit through [ADDRESS_691717] dose of trial  treatment.  
▪ Has received prior therapy with  anti–PD-1, anti –PD-L1, or  anti–PD-L2 agents, or 
if the subject has previously participated in [COMPANY_006] pembrolizumab  clinical trials.  
▪ Has a known history of human immunodeficiency virus (HIV) (HIV 1/2  antibodies).  
▪ Has known chronic or acute Hepatitis B (e.g. , HBsAg reactive) or Hepatitis C  
infection (e.g., HCV RNA [qualitative] is  detected).  
• Note: To qualify for enrollment, antiviral therapy for HBV must be given for at 
least [ADDRESS_691718] be less than 100 IU/mL prior to first dose 
of study  
 
drug. Those on active HBV therapy with viral loads under 100 IU/mL should stay on  
31 
 the same therapy throughout trial treatment. Those subjects who are anti -HBc (+),  and 
negative for HBsAg, and negative for anti -HBs, and have an HBV viral load under  
100 IU/mL do not require HBV anti -viral prophylaxis, but need close  monitoring.  
▪ Has dual infection with HBV/HCV or other hepatitis combinations at study  entry.  
▪ Has received a live vaccine within 30 days of planned start of study therapy 
(Cycle  1, Day  1). 
• Note: The killed virus vaccines used for seasonal influenza vaccines for injection  
are allowed; however intranasal influenza vaccines (e.g., FluMist®) are live  
attenuated vaccines and are not  allowed.  
 
6.3. Inclusion of Women and Minorities  
Both men and women of all races and ethnic groups are eligible for this  trial.  
Table 2. Inclusion of Women and Minorities  
Accrual Ta rgets 
Ethnic Category Sex/Gender 
Females  Males  Total  
Hisp anic or Latino 4 + 4 = 8 
Not Hisp anic or Latino 11 + 12 = 23 
Ethnic Category: To tal of all 
subjects 15 + 16 = 31 
Racial Ca tegory 
Asian 2 + 2 = 4 
Black or African Am erican 2 + 2 = 4 
White 11 + 12 = 23 
Racial Ca tegory: To tal of all 
subjects 15 + 16 = [ADDRESS_691719] 
dose level is deemed intolerable (≥ 2 DLTs), we will accrue 6 subjects at a lower dose level 
and complete 31 subjects (25 additional) at that dose level. Thus the maximum number of 
subjects enrolled  in this study will be  37. 
 
Participation is voluntary. The patient must be aware of the neoplastic nature of h is/her  
disease and willingly consent after being informed of the procedures to be followed, the  
[ADDRESS_691720] discontinues/withdraws prior to trial completion, all applicable  activities 
scheduled for the final trial visit should be performed at the time of discontinua tion. Any 
adverse events which are present at the time of discontinuation/withdrawal should be followed  
in accordance with the safety requirements outlined in Section 10.[ADDRESS_691721] -study treatment and survival as described.  Subjects 
who a) attain a CR or b) complete 24 months of treatment with pembrolizumab may  
discontinue treatment with the option of restar ting treatment in the future after consultation 
with the  sponsor. After discontinuing treatment following assessment of CR, these subjects 
should return to  the site for a Safety Follow -up Visit (described in Section 6.6.1  and then 
proceed to the  Follow -Up Period of the study (described in Section  6.6.2 ). 
 
6.5.[ADDRESS_691722] may  be 
withdrawn by [CONTACT_80074], the  
trial plan is violated, or for administrative and/or other safety  reasons.  
 
A subject must be discontinued from the trial for any of the following  reasons:  
• The subject or legal representative withdraws  consent.  
• Confirmed radiographic disease  progression  
o Note : A subject may be granted an exception to continue on treatment  with 
confirmed radiographic progression if clinically stable or clinically  
improved.  
• Unacceptable adverse  experiences  
• Intercurrent illness that prevents further administration of  treatment  
• Investigator’s decision to withdraw the  subject  
• The subject has a confirmed positive serum pregnancy  test 
• Noncompliance with trial treatment or procedure  requirements  
• The subject is lost to  follow -up 
• Completed 24 months of uninterrupted treatment with pembrolizumab or  
35 administrations of study medication, whichever is  later.  
o Note: [ADDRESS_691723]  dose.  
Subjects who stop pembrolizumab after 24 months may be eligible for up to  
one year of additional study treatment if they progress after stoppi[INVESTIGATOR_532722].  
33 
 • Administrative  reasons  
 
6.5.2 Data Collection and Follow -up for Withdrawn  Subjects  
The End of Treatment  and Follow -up visit procedures  are listed  in Section  12.1 (Trial  Flow  Chart) 
and Section  12.3 (Administrative  Procedures).  After  the end of treatment,  each subject  will 
be followed  for 30 days for adverse  event  monitoring  (serious  adverse  events  will be collected  
for 90 days after the end of treatment as described in Section 10). Subjects who discontinue for  
reasons other than progressive disease will have post -treatment follow -up for disease status until  
disease progression,  initiating  a non-study  cancer  treatment,  withdrawing  consent  or 
becoming  lost to follow -up. After documented disease progression each subject will be followed 
by [CONTACT_226181],  withdrawal  of consent,  or the end of the study,  
whichever  occurs  first. 
 
6.6. Post-Treatment  Visits  
 
6.6.[ADDRESS_691724]. 
 
All AEs that occur prior to the Safety Follow -Up Visit should be recorded. Subjects with an  
AE of Grade >[ADDRESS_691725] -study anti -cancer treatment will be collected if new treatment  is 
initiated.  
 
6.6.3 Survival  Follow -Up 
Subjects, who experience disease progression (by [CONTACT_532780]) or start a new anti  –
cancer therapy, will move into the Survival Follow -Up Phase. Subjects should be 
contact[INVESTIGATOR_530] (e.g.,  by [CONTACT_180699]) every [ADDRESS_691726]  Eligibility.  
 
Obtain informed consent, by [CONTACT_532781], along with applicable institutional policies and federal  regulations.  
 
Only Investigators/Research personnel properly trained and delegated to consent subjects for  
this protocol will participate in the consenting  process. Furthermore, properly  delegated/trained 
Physician Investigators (e.g., MD, MD PhD) are required to sign/verify a protocol  specific 
Eligibility Checklist for each subject enrolled on the study, in addition to providing the  
relevant source documentation confirmation subject  eligibility.  
 
All participants must be centrally registered through the Central Registration Office  within 
Herbert Irving Comprehensive Cancer Center at CUMC prior to initiation of study  treatment. 
Registration hours are available Monday through Friday from 9:00am – 5:00pm EST  
(excluding holidays and weekends). Same day patient registrations (and after hour 
registrations) will  be accommodated on a case by [CONTACT_532782]/cases in a timely manner to the Central 
Registration  Office.  
 
CPDM Central Registration  Procedures:  
Within 48 hours of obtaining consent (excluding holidays and weekends), a  completed/signed 
IRB approved informed consent HIPAA fo rm, and demographics forms must be submitted to  
the CPDM Central Registration Office via an email to 
[EMAIL_10190]  or fax to [PHONE_3163], with the subject line 
“AAAxxxxx Pending Subject Registration  Request (PHI)”.  
Upon receipt, applicable subject information as well as a “pending eligibility” status will  be 
entered into HICCC’s institutional database. This status will remain until further  source 
documentation is made available to confirm overall patient eligibility. Required materials for  
all pending registration submissions are as  follows:  
 
• Completed/signed IRB approved/stamped Informed Consent Forms, including  
additional study ICFs (e.g., tissue, DNA, etc.), as  applicable.  
• The completed/signed IRB approved HIPAA Authorization  form  
• Completed/signed CPDM ICF  checklist  
• Completed/signed HICCC personal census  form  
• Completed/signed CPDM Demographics Note to  File 
 
In order to confirm eligibility s tatus, Investigators/designees (e.g., study specific  Clinical 
Research Coordinator/Research Nurse, etc.) must submit the following documentation to  the 
35 
 Central Registration Office via email or  fax: 
 
• The completed/signed study specific Eligibility Checklist (signed by [CONTACT_532783])  
 
• Copi[INVESTIGATOR_532723], including but not limited  to: 
o Copy of required laboratory test and procedure reports (e.g., hematology,  
serum chemistry, pregnancy test when applicable, MRI reports, CT/bone 
scans,  etc.) 
o Copy of pathology and surgical  reports  
o Copy of clinic note(s) or other appropriate medical records capturing the  
consent process informa tion, along with providing source documentation of 
any other items needed for screening/eligibility that are not captured in other  
source document forms (e.g., positive investigator statements of unique 
eligibility  items not captured via other direct source documentation, 
concomitant medication  lists, etc.)  
o Protocol deviation/waiver approvals (if  applicable)  
• Please note : subject line of email or fax should include the  
following: “ AAAR3554 Complete Subject Registration Request  
(PHI)”.  
Upon receipt of the above mentioned documentation, participant eligibility information will  
be verified by a qualified Central Registration Registrar. If any questions arise during the  
review process, queries in the form of emails will be addressed to the appli cable study team  
personnel for clarification prior to enrollment. All applicable finalized 
registration/eligibility  information will then be entered into HICCC’s institutional CTMS 
database by [CONTACT_532784]. Upon completion, an officia l subject 
registration notification email will be sent to  the PI/research team which will include 
eligibility/enrollment status, as well as subject  ID information. Protocol therapy may not be 
initiated prior to receipt of this notification from  the Central  Registration  Office.  
 
All screen fail/ineligible subjects, as well as subject’s who withdraw consent prior  to 
enrollment/initiation of protocol therapy must be submitted to the Central Registration 
office in  a manner analogous to the procedures noted above. Applicable source 
documentation will  be required within the corresponding  submissions.  
 
 
8. TREATMENT  PLAN  
 
8.1. Agent  Administration  
 
Treatment will be administered on an outpatient basis. Reported adverse events and  
potential risks for Pembrolizumab and Azacitidine are described in Section 10. There are no  
36 
 dose modifications for Pembrolizumab. No investigational or commercial agents or 
therapi[INVESTIGATOR_532724]'s  malignancy. The treatment to be used in this trial is outline below in Table  3. 
 
 
Table 3 Trial Treatment Schedule  
Drug  Dose/Potency  Dose  Frequency  Route  of 
Administration  Regimen  Use 
 
Pembrolizumab  200 mg Q3W  IV Infusion  Dosed every  21 
days beginning  
in week 3  of 
study.  Experimental  
Azacitidine  50 mg/m2 Q4W  SubQ  Day 1 to 5 of  on 
a 28-day cycle  Experimental  
 
The investigator shall take responsibility for and shall take all steps to maintain  appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of  trial 
treatments in accordance with the protocol and any applicable laws and  regulations.  
 
8.2. Dose Se lection/Modification  
8.2.1 Dose  Selection  
The rationale for selection of doses to be used in this trial is provided in Section 4 
Background and  Rationale.  
 
Details on preparation and administration of pembrolizumab (MK -3475) are pro vided in  the 
Pharmacy manual. Preparation and administration of azacitidine should be completed as per  
the approved product label. See Section  8.1 for general recommendations for  
administration.  
 
Body surface area (BSA) in m2  should be calculated per local  guidance.  
 
8.2.2 Dose Modification  (Escalation/Titration/Other)  
The Common Terminology Criteria for Adverse Events version 4.0 (CTCAE 4.0) must be  
used to grade the severity of adverse  events.  
 
If appropriate, the investigators may attribute each toxicity event to either one of  the 
investigational agents and use stepwise dose modifications according to Table [ADDRESS_691727]  
of care for dose adjustments. At the investigator’s discretion, dose modification according 
to Table  5 is allowed for intolerable Grade 2 -3 toxicities that are not specified in the tables  
below.  
 
8.3. Pembrolizumab  
8.2.3 General Concomitant Medication and Supportive Care  Guidelines  
 
8.2.4 Concomitant Medications/Vaccinations (allowed &  prohibited)  
Medications or vaccinations specifically prohibited in the exclusion criteria are not  allowed 
during the ongoing trial. If there is a clinical indication for one of these or other medications  
or vaccinations specifically prohibited during the trial, discontinuation from trial therapy  or 
vaccination may be required.  The investigator should discuss any questions regarding this  
with the [COMPANY_006] Clinical team. The final decision on any supportive thera py or vaccination 
rests with the investigator and/or the subject's primary  physician.  However, the decision to 
continue the subject on trial therapy or vaccination schedule requires the mutual agreement 
of the investigator, Sponsor -Investigator, and the subject.  
 
8.2.[ADDRESS_691728]’s  welfare  may be 
administered at the discretion of the investigator in keepi[INVESTIGATOR_12983].  All concomitant  medication  will be recorded  on the case report  form  (CRF)  
including  all prescription, over -the-counter (OTC), herbal supplements, and IV medications and 
fluids. If changes  occur during  the trial period,  documentation  of drug dosage,  frequency,  
route,  and date may also be included on the  CRF.  
All concomitant medications received within [ADDRESS_691729] dose of trial treatment should be recorded  for SAEs  and 
ECIs as defined in Section  10. 
 
8.2.6 Prohibited Concomitant  Medications  
Subjects are prohibited from receiving the following therapi[INVESTIGATOR_532725] (including retreatment for post -complete response relapse) of this  trial:  
 
• Antineoplastic systemic chemotherapy or biological  therapy  
• Immunotherapy not specified in this  protocol  
• Chemotherapy not specified in this  protocol  
• Investigational agents other than  pembrolizumab  
• Radiation therapy  
o Note: Radiation therapy to a symptomatic solitary lesion or to the brain may be 
allowed at the investigator’s discretion.  
• Live vaccines  within  [ADDRESS_691730] dose of trial treatment  and while  
participating in  the trial. Examples  of live vaccines  include,  but are not limited  to, 
38 
 the following: measles,  mumps,  rubella,  varicella/zoster,  yellow  fever,  rabies,  BCG,  and 
typhoid  vaccine.  
• Systemic glucocorticoids for any purpose other than to modulate symptoms from an  
event of  clinical  interest  of suspected  immunologic  etiology.  The use of physiologic  
doses  of corticosteroids may be approved after consultation with the  PI. 
 
Subjects who, in the assessment by [CONTACT_093], require the use of any of the  aforementioned 
treatments for clinical management should be removed from the trial. Subjects may receive  other 
medications that the investigator deems to be medically  necess ary. 
 
The Exclusion Criteria describes other medications which are prohibited in this  trial. 
There are no prohibited therapi[INVESTIGATOR_3927] -Treatment Follow -up Phase.  
8.2.[ADDRESS_691731], and in severe cases, immune -related toxicities may require acute 
management with topi[INVESTIGATOR_8826], systemic corticosteroids, or other immunosuppressive 
agents. The treatment guidelines are intended to be applied when the  investigator determines 
the events to be related to trial  treatment.  
 
Note: if after the evaluation the event is determined not to be related, the investigator does  not 
need to follow the treatment guidance (as outlined  below).  
 
MANAGEMENT GUIDELINES  
▪ Immune -related h epati tis 
Immune -related hepatitis has been associated with the administration of 
pembrolizumab. Patients with right upper quadrant pain and/or unexplained nausea or 
vomiting should have liver function tests ( LFTs) performed immediately and reviewed 
before administr ation of the next dose of study drug.  
 
39 
 For patients with elevated LFTs, concurrent medication, viral hepatitis, biliary 
obstruction, and toxic or neoplastic etiologies should be considered and addressed, as 
appropriate.  
 
o For Grade 1 events , continue pembrolizumab and monitor LFTs until values 
resolve to within normal limits or to baseline values.  
 
o For Grade 2 events  of >5 days’ duration :  
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
Pembrolizumab may  be withheld for a longer period of time (i.e. >12 
weeks after event onset) to allow for corticosteroids (if initiated) to be 
reduced to the equivalent of 10 mg/day or less of oral predni sone. The 
acceptable length of the extended period of time will be determined by 
[CONTACT_093].  
▪ Initiate treatment with systemic corticosteroids equivalent to 1 -2 
mg/kg/day oral prednisone.  
▪ Monitor liver function tests more frequently until returned  to baseline 
values (consider  weekly).  
▪ If event resolves to Grade [ADDRESS_691732] be tapered over no less 
than 4 weeks to the equivalent of 10 mg/day oral prednisone or less 
before pembrolizum ab may be resumed.  
 
o For Grade 3 -4 events : 
▪ Permanently discontinue pembrolizumab.  
▪ Consider referral to gastrointestinal specialist for evaluation and liver 
biopsy to establish etiology of hepatic injury.  
▪ Initiate treatment with systemic corticosteroids equivalent to 1 -2 
mg/kg/day oral prednisone.  
▪ If the event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
▪ If event resolves to Grade 1 or better, taper corticosteroids over no less 
than 4 weeks.  
 
▪ Immune -related p neumonitis  
Dyspnea, cough, fatigue, hypoxia, pneumonitis, and pulmonary infiltrates have been 
associated with the administration of pembrolizumab. Patients will be assessed for 
pulmonary signs and symptoms throughout the  study and will have computed 
tomography (CT) scans of the chest performed at every tumor assessment.  
 
All pulmonary events should be thoroughly evaluated for other commonly reported 
etiologies such as pneumonia or other infection, lymphangitic carcinomatosis, 
40 
 pulmonary embolism, heart failure, chronic obstructive pulmonary disease, or 
pulmonary hypertensio n.  
 
Management guidelines for pulmonary events, including pneumonitis:  
o For Grade [ADDRESS_691733].  
 
o For Grade 2 events :  
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
Pembrolizumab may  be withheld for a longer period of time (i.e. >12 
weeks after event onset) to allow for corticosteroids (if initiated) to be 
reduced to the equivalent of 10 mg/day or less of oral predni sone.  
▪ Initiate treatment  with systemic corticosteroids  equivalent to 1 -2 
mg/kg/day  oral prednisone .  
▪ Refer patient to pulmonary specialist and consider bronchoscopic 
alveolar lavage.   
▪ When  symptoms improve to Grade 1 or less, resume pembrolizumab. 
Steroid  taper should be started and continued over  no less than 4  weeks.   
 
o For Grade 3 -4 events : 
▪ Permanent ly discontinue pembrolizumab.  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day  
oral prednisone.   
▪ If the event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
▪ If event resolves to Grade 1 or better, taper corticosteroids over no 
less than 4 weeks.  
 
o Add prophylactic antibiotics for opportun istic infections in the case of  
prolonged steroid  administration.  
 
▪ Immune -related c olitis  
Subjects should be carefully monitored for signs and symptoms of enterocolitis (such  as 
diarrhea, abdominal pain, blood or mucus in stools, with or without fever) and of  bowel 
perforation (such as peritoneal signs and  ileus).  
 
All events of diarrhea or colitis should be thoroughly evaluated for other more common 
etiologies. For events of significant duration or magnitude or associated with signs of 
systemic i nflammation or acute -phase reactants (e.g. increased C -reactive protein, 
platelet count, or bandemia): Perform sigmoidoscopy (or colonoscopy, if appropriate) 
with colonic biopsy, with three to five specimens for standard paraffin block to check 
41 
 for inflamm ation and lymphocytic infiltrates to confirm colitis diagnosis.  
 
o All subjects who experience diarrhea/colitis should be advised to drink  liberal 
quantities of clear fluids. If sufficient oral fluid intake is not feasible, fluid  and 
electrolytes should be substituted via IV infusion.  
 
o For Grade [ADDRESS_691734] 
>7 days, endoscopy is recommended.  
 
o For Grade 2 diarrhea  or colitis :  
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
Pembrolizumab may  be withheld for a longer period of time (i.e. >12 
weeks after event onset) to allow for corticosteroids (if initiated) to be 
reduced to the equivalent of 10 mg/day or less of oral prednisone.  
▪ Refer to GI specialist for evaluation and confirmatory biopsy.  
▪ For recurrent events or events that persist >5 days, i nitiate treatment 
with corticosteroids equivalent to  1-2 mg/kg/day oral prednisone.   
▪ If symptoms improve to Grade [ADDRESS_691735] be tapered over no less 
than 4 weeks to the equivalent of 10 mg/day oral prednisone or less 
before pembrolizumab may be resumed.  
 
o For Grade 3 diarrhea or colitis : 
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
Pembrolizumab may  be withheld for a longer period of time (i.e. >12 
weeks after event onset) to allow for corticosteroids (if initiated) to be 
reduced to the equivalent of 10 mg/day or less of oral prednisone.  
▪ Refer to GI specialist for evaluation a nd confirmatory biopsy.  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day IV 
methylprednisolone and convert to 1 -2 mg/kg/day oral prednisone or 
equivalent upon improvement.   
▪ If symptoms improve to Grade [ADDRESS_691736] be tapered over no less 
than 4 weeks to the equivalent of 10 mg/day oral prednisone or less 
before pembrolizumab may be resumed.  
 
o For Grade 4 diarrhea  or colitis :  
▪ Permanently discontinue pem brolizumab.  
▪ Refer to GI specialist for evaluation and confirmatory biopsy.  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day IV 
methylprednisolone and convert to 1 -2 mg/kg/day oral prednisone or 
equivalent upon improvement.   
▪ If the event does not improve within 48 hours after initiating corticosteroids, 
42 
 consider adding an immunosuppressive agent.  
▪ If the event resolves to Grade 1 or better, taper corticosteroids over no less than 4 
weeks.  
 
▪ Immune -related t ype 1 diabetes mellitus  (if new onset, including diabetic 
ketoacidosis [DKA] or ≥  Grade 3 Hyperglycemia, if associated with ketosis (ketonuria) 
or metabolic acidosis  (DKA)  
 
o For new onset T1DM or Grade 3 -4 Hyperglycemia  
▪ Withhold pembrolizumab  
▪ Insulin replacement therapy is recommended for T1DM and for Grade  
3-4 hyperglycemia associated with metabolic acidosis or  ketonuria.  
▪ Monitor for glucose control.  
▪ Evaluate patients with plasma glucose and a metabolic panel,  
urine ketones, HbA1c, and  C-peptide.  
▪ Resume pembrolizumab when symptoms resolve and glucose 
levels are stable.  
 
▪ Immune -related h ypophysitis  
Patients with unexplained symptoms such as headache, fatigue, myalgias, impotence, 
constipation, or mental status change should be investigated for the presence  of thyroid, 
pi[INVESTIGATOR_2117], or adrenal endocrinopathies. The patient should be referred to an 
endocrinologist if an endocrinopathy is suspected. Thyroid -stimulating hormone (TSH) 
and free triiodothyronine and thyroxine levels should be measured to determine wh ether 
thyroid abnormalities are present. Pi[INVESTIGATOR_33418] (e.g. TSH, 
growth hormone, luteinizing hormone, follicle -stimulating hormone, testosterone, 
prolactin, adrenocorticotropic hormone [ACTH] levels, and ACTH stimulation test ) and 
magnetic resonance imaging (MRI) of the brain (with detailed pi[INVESTIGATOR_33419]) may 
help to differentiate primary pi[INVESTIGATOR_33420].  
 
o For Grade 2  or 3 events :  
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
Pembrolizumab may  be withheld for a longer period of time (i.e. >12 
weeks after event onset) to allow for corticosteroids (if initiated) to be 
reduced to the equivalent of 10 mg/day or less of oral prednisone.  
▪ Refer patient to endocrinol ogist.  
▪ Perform brain MRI (pi[INVESTIGATOR_33421]).  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day IV 
methylprednisolone and convert to 1 -2 mg/kg/day oral prednisone or 
equivalent upon improvement.   
▪ Initiate hormone replacement if clinicall y indicated.  
43 
 ▪ If symptoms improve to Grade [ADDRESS_691737] be tapered over no less 
than 4 weeks to the equivalent of 10 mg/day oral prednisone or less 
before pembrolizumab may be resumed.  
▪ For recurrent hypophysitis, treat as Grade 4 event.  
 
o For Grade 4 event :  
▪ Permanently discontinue pembrolizumab.  
▪ Refer patient to endocrinologist.  
▪ Perform brain MRI (pi[INVESTIGATOR_33421]).  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day IV 
methylprednisolone and convert to 1 -2 mg/kg/day oral prednisone or 
equivalent upon improvement.   
▪ Initiate hormone replacement if clinically indicated.  
 
▪ Immune -related h yperthyroidism or  hypothyroidism  
Patients with unexplained symptoms such as headache, fatigue, myalgias, impotence, 
constipation, or mental status change should be investigated for the presence of thyroid, 
pi[INVESTIGATOR_2117], or adrenal endocrinopathies. The patient should be referred to an 
endocrinologist if an endocrinop athy is suspected. Thyroid -stimulating hormone (TSH) 
and free triiodothyronine and thyroxine levels should be measured to determine whether 
thyroid abnormalities are present. Pi[INVESTIGATOR_33418] (e.g. TSH, 
growth hormone, luteinizin g hormone, follicle -stimulating hormone, testosterone, 
prolactin, adrenocorticotropic hormone [ACTH] levels, and ACTH stimulation test) and 
magnetic resonance imaging (MRI) of the brain (with detailed pi[INVESTIGATOR_33419]) may 
help to differentiate primary p ituitary insufficiency from primary adrenal insufficiency.  
 
Thyroid disorders can occur at any time during treatment. Monitor patients for changes  
in thyroid function (at the start of treatment, periodically during treatment, and as  
indicated based on clin ical evaluation) and for clinical signs and symptoms of thyroid  
disorders.  
 
o Asymptomatic hypothyroidism : 
▪ Continue pembrolizumab  
▪ Initiate treatment with thyroid replacement hormone per standard of 
care 
 
o Symptomatic hypothyroidism : 
▪ Withhold pembrolizumab  
▪ Initiate treatment with thyroid replacement hormone per standard of 
care 
▪ Consider referral to endocrinology  
44 
 ▪ Resume pembrolizumab when symptoms are controlled and thyroid 
function is normal.  
 
o Asymptomatic hyperthyroidism : 
▪ TSH  0.1 mU/L and  0.5 mU/L  
• Continue pembrolizumab  
• Monitor TSH every 4 weeks  
▪ TSH <0.1 mU/L:  
• Follow guidelines for symptomatic hyperthyroidism.  
 
o Symptomatic hyperthyroidism : 
▪ Withhold pembrolizumab  
▪ Initiate treatment with anti -thyroid drug such as methimazole or 
carbimazole as needed  
▪ Consider referral to endocrinology  
▪ Resume pembrolizumab when symptoms are controlled and thyroid 
function is normal.  
 
▪ Immune -related adrenal insufficiency  
Patients with unexplained symptoms such as headache, fatigue, myalgias, impoten ce, 
constipation, or mental status change should be investigated for the presence of thyroid, 
pi[INVESTIGATOR_2117], or adrenal endocrinopathies. The patient should be referred to an 
endocrinologist if an endocrinopathy is suspected. Thyroid -stimulating hormone (TSH) 
and free triiodothyronine and thyroxine levels should be measured to determine whether 
thyroid abnormalities are present. Pi[INVESTIGATOR_33418] (e.g. TSH, 
growth hormone, luteinizing hormone, follicle -stimulating hormone, testosterone , 
prolactin, adrenocorticotropic hormone [ACTH] levels, and ACTH stimulation test) and 
magnetic resonance imaging (MRI) of the brain (with detailed pi[INVESTIGATOR_33419]) may 
help to differentiate primary pi[INVESTIGATOR_532726].  
 
o Symptomatic adrenal insufficiency, Grade 2 -4: 
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
Pembrolizumab may  be withheld for a longer period of time (i.e. >12 
weeks after event onset) to allow for corticosteroids (if initiated) to be 
reduced to the equivalent of 10 mg/day or less of oral prednisone.  
▪ Refer patient to endocrinologist.  
▪ Perform appropriate imaging.  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day IV 
methylprednisolone and convert to 1 -2 mg/kg/day oral prednisone or 
equivalent upon improvement.   
▪ If event resolves to Grade [ADDRESS_691738] be tapered over no less than 4 weeks to the 
45 
 equivalent of 10 mg/day oral prednisone or less before pembrolizumab 
may be resumed.  
 
▪ Immune -mediated nephritis  
Patients with abnormal renal fu nction should be evaluated and treated for other more 
common etiologies (including prerenal and postrenal causes, and concomitant 
medications such as non -steroidal anti -inflammatory drugs). Refer the patient to a renal 
specialist if clinically indicated. A  renal biopsy may be required to enable a definitive 
diagnosis and appropriate treatment.  
 
o For Grade 1  events: Continue pembrolizumab and monitor kidney function 
closely until values resolve to within normal limits or to baseline values.  
 
o Grade 2 events : 
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
Pembrolizumab may  be withheld for a longer  period of time (i.e. >12 
weeks after event onset) to allow for corticosteroids (if initiated) to be 
reduced to the equivalent of 10 mg/day or less of oral prednisone.  
▪ Refer patient to a renal specialist.  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day 
oral prednisone.   
▪ If event resolves to Grade [ADDRESS_691739] be tapered over no less than 4 weeks to the 
equivalent of 10 mg/day oral prednisone or less before pembrolizumab 
may be resumed.  
 
o For Grade 3  or 4 events : 
▪ Permanently discontinue pembrolizumab.  
▪ Refer patient to a renal specialist.  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day 
oral prednisone.   
▪ If the event does not improve within 48 hours after initiating corticosteroids, 
consider adding an immunosuppressive agent.  
▪ If event resolves to Grade 1 or better, taper corticosteroids over no less 
than 4 weeks.  
 
▪ Immune -mediated dermatologic events  
The majority of rashes are mild and self -limited, with or without pruritus. A 
dermatologist should evaluate persistent and/or severe rash or pruritus. A biopsy should 
be considered unless contraindicated.  
 
o Grade 1 :  
▪ Continue pembrolizumab.  
46 
 ▪ Consider treatment with  topi[INVESTIGATOR_40826]/or other 
symptomatic therapy (e.g., antihistamines).  
 
o Grade 2 : 
▪ Continue pembrolizumab.  
▪ Consider patient referral to a dermatologist.  
▪ Initiate treatment with  topi[INVESTIGATOR_11977] s. 
▪ Consider treatment with higher -potency topi[INVESTIGATOR_379493].  
 
o Grade 3 :  
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
Pembrolizumab may  be withheld for a longer period of time (i.e. >12 
weeks after event onset) to allow for corticosteroids (if initiated) to be 
reduced to the equivalent of 10 mg/day or less of oral prednisone.  
▪ Refer patient to a dermatologist.  
▪ Initiate treatment with corti costeroids equivalent to 10 mg/day oral 
prednisone, increasing dose to 1 -2 mg/kg/day if event does not improve 
within 48 -72 hours.  
▪ If event resolves to Grade [ADDRESS_691740] be tapered over no less than 4 weeks to the 
equivalent of 10 mg/day oral prednisone or less before pembrolizumab 
may be resumed.  
 
o Grade 4 : 
▪ Permanently discontinue pembrolizumab.  
 
▪ Immune -mediated ocular events  
An ophthalmologist should evaluate visual complaints (e.g. uveitis, retinal events).  
 
o Grade 1 :  
▪ Continue pembrolizumab.  
▪ Referral to an ophthalmologist is strongly recommended.  
▪ Initiate treatment with topi[INVESTIGATOR_33422].  
▪ If symptoms persist, treat as a Grade 2 event.  
 
o Grade 2 :  
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
Pembrolizumab may  be withheld for a longer period of time (i.e. >12 
weeks after event onset) to allow for cort icosteroids (if initiated) to be 
47 
 reduced to the equivalent of 10 mg/day or less of oral prednisone.  
▪ Referral to an ophthalmologist is strongly recommended.  
▪ Initiate treatment with topi[INVESTIGATOR_33422].  
▪ If event resolves to Grade [ADDRESS_691741] be tapered over no less than 4 weeks to the 
equivalent of 10 mg/day oral prednisone or less before pembrolizumab 
may be resumed.  
 
o Grade 3 or 4 : 
▪ Permanently discontinue pembrolizumab.  
▪ Refer patient to an ophthalmologist.  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day oral 
prednisone.  
▪ If event resolves to Grade 1 or better, tap er corticosteroids over no less 
than 4 weeks.  
 
▪ Immune -related pancreatitis  
Symptoms of abdominal pain associated with elevations of amylase and lipase, 
suggestive of pancreatitis, have been associated with the administration of 
pembrolizumab. The differential diagnosis of acute abdominal pain should include 
pancreatitis. Appropriate work up should include an evaluation for ductal obstruction, 
as well as serum amylase and lipase tests.  
 
o Amylase and/or lipase elevation, Grade 2 : 
▪ Amylase and/or lipase >1.[ADDRESS_691742]  
• Continue pembrolizumab  
• Monitor amylase and lipase weekly  
• For prolonged elevation (e.g., >3 weeks), consider treatment 
with corticosteroids equivalent to 10 mg/day oral prednisone.  
▪ Asymptomatic with amylase and/or lipase >2.[ADDRESS_691743]  
• Treat as a Grade 3 event  
 
o Amylase and/or lipase elevation, Grade 3 or 4 : 
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
Pembrolizumab may  be withheld for a longer period of time (i.e. >12 
weeks after event onset) to allow for corticosteroids (if initiated) to be 
reduced to the equivalent of 10 mg/day or less of or al prednisone.  
▪ Refer patient to a GI specialist.  
▪ Monitor amylase and lipase every other day.  
▪ If no improvement, consider treatment with corticosteroids equivalent 
48 
 to 1-2 mg/kg/day oral prednisone.  
▪ If event resolves to Grade [ADDRESS_691744] be tapered over no less than 4 weeks to the 
equivalent of 10 mg/day oral prednisone or less before pembrolizumab 
may be resumed.  
▪ For recurrent events, permanently discontinue pembrolizumab.  
 
o Immune -related pancreatitis, Grade 2 or 3 : 
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
Pembrolizumab may  be withheld for a longer period of time (i .e. >12 
weeks after event onset) to allow for corticosteroids (if initiated) to be 
reduced to the equivalent of 10 mg/day or less of oral prednisone.  
▪ Refer patient to a GI specialist.  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day IV 
methylprednisolone and convert to 1 -2 mg/kg/day oral prednisone or 
equivalent upon improvement.   
▪ If event resolves to Grade [ADDRESS_691745] be tapered over no less than 4 weeks to the 
equivalent of 10 mg/day oral prednisone or less before pembrolizumab 
may be resumed.  
▪ For recurrent events, permanently discontinue pembrolizumab.  
 
o Immune -related pancreatitis, Grade 4 : 
▪ Permanently discontinue pembro lizumab.  
▪ Refer patient to a GI specialist.  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day IV 
methylprednisolone and convert to 1 -2 mg/kg/day oral prednisone or 
equivalent upon improvement.   
▪ If the event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
▪ If event resolves to Grade 1 or better, taper corticosteroids over no less 
than 4 weeks.  
 
▪ Immune -related myocarditis  
Immune -related myocarditis should be suspected in any patient presenting with signs 
or symptoms suggestive of myocarditis, including, but not limited to dyspnea, chest 
pain, fatigue, decreased exercise tolerance, or syncope. Immune -related myocarditis 
needs to be distinguished from myocarditis resulting f rom infection (commonly viral, 
e.g., in a patient who reports a history of gastrointestinal illness), ischemic events, 
underlying arrhythmias, exacerbation of preexisting cardiac conditions, or progression 
of malignancy.  
[ADDRESS_691746] should be consulted. An 
endomyocardial biopsy may be consider ed to enable a definitive diagnosis and 
appropriate treatment, if clinically indicated.   
 
o For Grade 2 events : 
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
Pembrolizumab may  be withheld for a longer period of time (i.e. >12 
weeks after event  onset) to allow for corticosteroids (if initiated) to be 
reduced to the equivalent of 10 mg/day or less of oral prednisone.  
▪ Refer patient to  a cardiologist.  
▪ Initiate treatment as per institutional guidelines.  
▪ Consider treatment with corticosteroids equivalent to 1 -2 mg/kg/day IV 
methylprednisolone and convert to 1 -2 mg/kg/day oral prednisone or 
equivalent upon improvement.  
▪ If event resolves to Grade [ADDRESS_691747] be tapered over no less than 4 weeks to the 
equivalent of 10 mg/day oral prednisone or less before pembrolizumab 
may be resumed.  
 
o For Grade 3 or 4 events : 
▪ Permanently discontinue pembrolizumab.  
▪ Refer patient to a cardiologist.  
▪ Initiate treatment as per institutional guidelines.  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day IV 
methylprednisolone and convert to 1 -2 mg/kg/day oral prednisone or 
equivalent upon improvement.  
▪ If the eve nt does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
▪ If event resolves to Grade 1 or better, taper corticosteroids over no less 
than 4 weeks.  
 
▪ Immune -related neuropathies (i.e. myasthenic syndrom e/myasthenia gravis, 
Guillain -Barre syndrome)  
Patients may present with signs and symptoms of sensory and/or motor neuropathy. 
Diagnostic work up is essential for an accurate characterization to differentiate between 
alternative etiologies.  
 
o Immune -related neuropathy, Grade 1 : Continue pembrolizumab and 
investigate etiology.  
50 
  
o Immune -related neuropathy, Grade 2 :  
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
Pembrolizumab may  be withheld for a longer period of time (i.e. >12 
weeks after event onset) to allow for corticosteroids (if initiated) to be 
reduced to the equivalent of 10 mg/day or less of oral prednisone.  
▪ Investigate etiology.  
▪ Initiate treatment as per institutional g uidelines.  
▪ If event resolves to Grade [ADDRESS_691748] be tapered over no less than 4 weeks to the 
equivalent of 10 mg/day oral prednisone or l ess before pembrolizumab 
may be resumed . 
 
o Immune -related neuropathy, Grade 3 or 4 : 
▪ Permanently discontinue pembrolizumab.  
▪ Initiate treatment as per institutional guidelines.  
 
o Myasthenia gravis and Guillain -Barre syndrome (any grade) : 
▪ Permanently discontinue pembrolizumab.  
▪ Refer patient to a neurologist.  
▪ Initiate treatment as per institutional guidelines.  
▪ Consider treatment with corticosteroids equivalent to 1 -2 mg/kg/day oral 
or IV prednisone.  
 
▪ Immune -related meningo encephalitis  
Immune -related meningoencephalitis should be suspected in any patient presenting 
with signs or symptoms suggestive of meningitis or encephalitis, including, but not 
limited to, headache, neck pain, confusion, seizure, motor or sensory dysfunction, and 
altered or depressed level of consciousness. Encephalopathy from metabolic or 
electrolyte imbalances needs to be distinguished from potential meningoencephalitis 
resulting from infection (bacterial, viral, or fungal) or progression of malignancy, or 
secondary to a paraneoplastic process.  
 
All patients being considered for meningoencephalitis should be urgently evaluated 
with a CT scan and/or MRI scan of the brain to evaluate for metastasis, inflammation, 
or edema. If deemed safe by [CONTACT_1963], a lum bar puncture should be 
performed and a neurologist should be consulted.  
 
Patients with signs and symptoms of meningoencephalitis, in the absence of an 
identified alternate etiology, should be treated according to the guidelines.  
 
o Immune -related meningoence phalitis (all grades) : 
51 
 ▪ Permanently discontinue pembrolizumab.  
▪ Refer patient to a neurologist.  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day IV 
methylprednisolone and convert to 1 -2 mg/kg/day oral prednisone or 
equivalent upon improvem ent. 
▪ If the event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
▪ If event resolves to Grade 1 or better, taper corticosteroids over no less 
than 4 weeks.  
 
▪ Myositis  
Myositis or inflammatory myopathies are a group of disorders sharing the common 
feature of inflammatory muscle injury; dermatomyositis and polymyositis are among 
the most common disorders. Initial diagnosis is based on clinical (muscle weakness, 
muscle pain, skin rash  in dermatomyositis), biochemical (serum creatine kinase 
increase), and imaging (electromyography/MRI) features, and is confirmed with a 
muscle biopsy.  
 
o For Grade 1 events : Continue pembrolizumab, refer patient to a rheumatologist 
or neurologist, and initi ate treatment as per institutional guidelines.  
 
o For Grade 2  events:  
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
Pembrolizumab may  be withheld for a longer period of time (i.e. >12 
weeks after event onset) to allow for corticosteroids (if i nitiated) to be 
reduced to the equivalent of 10 mg/day or less of oral prednisone.  
▪ Refer patient to a rheumatologist or neurologist.  
▪ Initiate treatment as per institutional guidelines.  
▪ Consider treatment with corticosteroids equivalent to 1 -2 mg/kg/day IV 
methylprednisolone and convert to 1 -2 mg/kg/day oral prednisone or 
equivalent upon improvement.  
▪ If corticosteroids are initiated and the event does not improve within 48 
hours after initiating corticosteroids, consider adding an 
immunosuppressive agent.  
▪ If event resolves to Grade [ADDRESS_691749] be tapered over no less than 4 weeks to the 
equivalent of 10 mg/day oral p rednisone or less before pembrolizumab 
may be resumed.  
 
o For Grade 3  events:  
▪ Withhold pembrolizumab for up to 12 weeks after event onset. 
52 
 Pembrolizumab may  be withheld for a longer period of time (i.e. >12 
weeks after event onset) to allow for corticosteroids (if initiated) to be 
reduced to the equivalent of 10 mg/day or less of oral prednisone.  
▪ Refer patient to a rheumatologist or neurologist.  
▪ Initiate trea tment as per institutional guidelines. Respi[INVESTIGATOR_408018].  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day IV 
methylprednisolone, or higher -dose bolus if patient is severely 
compromised (e.g., cardi ac or respi[INVESTIGATOR_1856], dysphagia, or 
weakness that severely limits mobility); convert to 1 -2 mg/kg/day oral 
prednisone or equivalent upon improvement.  
▪ If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immun osuppressive agent.  
▪ If event resolves to Grade [ADDRESS_691750] be tapered over no less than 4 weeks to the 
equivalent of 10 mg/day oral predni sone or less before pembrolizumab 
may be resumed.  
▪ For recurrent events, treat as a Grade 4 event.  
 
o For Grade 4  events:  
▪ Permanently discontinue pembrolizumab.  
▪ Refer patient to a rheumatologist or neurologist.  
▪ Initiate treatment as per institutional guidelin es. Respi[INVESTIGATOR_408018].  
▪ Initiate treatment with corticosteroids equivalent to 1 -2 mg/kg/day IV 
methylprednisolone, or higher -dose bolus if patient is severely 
compromised (e.g., cardiac or respi[INVESTIGATOR_1856], dysphag ia, or 
weakness that severely limits mobility); convert to 1 -2 mg/kg/day oral 
prednisone or equivalent upon improvement.  
▪ If the event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
▪ If event re solves to Grade 1 or better, taper corticosteroids over no less 
than 4 weeks.  
 
▪ Infusion -related  reactions  
 
Signs and symptoms usually develop during or shortly after drug infusion and  
generally resolve completely within 24 hours of completion of  infusion.  No 
premedication is indicated for the administration of Cycle 1 of pembrolizumab. 
However, patients who experience an IRR with Cycle 1 of pembrolizumab may 
receive premedication with antihistamines or antipyretics/analgesics (e.g., 
acetaminophen)  for subsequent infusions.  
53 
  
Table 4 Infusion Reaction Treatment Guidelines  
 
NCI CTCAE  Grade  Treatment  Premedication at  subsequent 
dosing  
Grade  1 
Mild reaction; infusion  interruption 
not indicated; intervention  not 
indicated  Increase monitoring of vital signs as  medically 
indicated until the subject is deemed  medically 
stable in the opi[INVESTIGATOR_15863].  None  
Grade  2 
Requires infusion interruption  but 
responds promptly to  symptomatic 
treatment (e.g.,  antihistamines, 
NSAIDS, narcotics, IV fluids); 
prophylactic medications indicated  for 
< =24  hrs Stop Infusion and monitor  symptoms. 
Additional appropriate medical therapy  may 
include but is not limited  to: 
IV fluids 
Antihistamines 
NSAIDS  
Acetaminophen 
Narc otics 
Increase monitoring of vital signs as  medically 
indicated until the subject is deemed  medically 
stable in the opi[INVESTIGATOR_15863].  
If symptoms resolve within one hour of  stoppi[INVESTIGATOR_108607], the infusion may be restarted  at 
50% of the original infusion rate (e.g., from  100 
mL/hr to 50 mL/hr). Otherwise dosing will  be 
held until symptoms resolve and the  subject 
should be premedicated for the next  scheduled 
dose.  
Subjects who develop Grade [ADDRESS_691751] may be premedicated  1.5h 
(± 30 minutes) prior to infusion  of 
pembrolizumab (MK -3475)  with:  
 
Diphenhydramine 50 mg po  (or 
equivalent dose of  antihistamine).  
 
Acetaminophen 500 -1000 mg  po 
(or equivalent dose of  antipyretic).  
Grades 3 or  4 
Grade  3: 
Prolonged (i.e., not rapi[INVESTIGATOR_532727]/or 
brief interruption of  infusion); 
recurrence of symptoms  following 
initial improvement;  hospi[INVESTIGATOR_532728] 
(e.g., renal impairment,  pulmonary 
infiltrates)  
Grade  4: 
Life-threatening; pressor or  ventilatory 
support  indicated  Stop  Infusion.  
Additional appropriate medical therapy  may 
include but is not limited  to: 
IV fluids 
Antihistamines 
NSAIDS  
Acetaminophen 
Narcotics 
Oxygen 
Pressors 
Corticosteroids 
Epi[INVESTIGATOR_532729].  
Hospi[INVESTIGATOR_199892].  
Subject is permanently discontinued  from 
further trial treatment  administration.  No subsequent  dosing  
Appropriate  resuscitation  equipment  should  be available  in the room  and a physician  readily  available  during  the period  of drug 
administration.  
 
8.4. Azacitidine  
Azacitidine is supplied as a lyophilized powder in a single -dose vial. Each vial contains 100  
mg of azacitidine. Azacitidine is administered at a dose of 50 mg/m2 by [CONTACT_532785], in  
rotating sites (thigh, abdomen, or upper arm) repeated  for [ADDRESS_691752] shown that azacitidine does not cause inhib ition 
of CYP2B6 and CYP2C8 but the potential of azacitidine to inhibit other cytochrome P450  
enzymes is not known. Other in vitro studies indicate that azacitidine does not induce CYP 
1A2, 2C19,  or 3A4/5.  
 
8.5. Diet/Activity/Other Considerations  
8.2.[ADDRESS_691753] 
azoospermia (whether due to having had a vasectomy or due to an underlying  medical 
condition).  
 
Female subjects will be considered of non -reproductive potential if they are  either:  
(1) postmenopausal (defined as at least 12 months with no menses without  an 
alternative medical cause; in women ≥45 years of age a high  follicle -stimulating 
hormone [FSH] level in the postmenopausal range may be used to confirm a  
post- menopausal state in women not using hormonal contraception or  
hormonal replacement therapy. In the absence of [ADDRESS_691754] two FSH measurements should be  obtained);  
• OR 
 
 
• OR 
 
(2) have had a hysterectomy and/or bilateral oophorectomy, bilateral  salpi[INVESTIGATOR_1656], or 
bilateral tubal ligation/occlusion at least 6 weeks prior to  screening;  
 
(3) has a congenital or acquired condition that prevents  childbearing.  
 
Female and male subjects of reproductive potential must agree to avoid becoming pregnant  or 
impregnating a partner, respectively, while receiving pembrolizumab and for [ADDRESS_691755] comply with one of the  following:  
(1) practice abstinence* from heterosexual  activity;  
• OR 
55 
  
(2) use (or have their partner use) acceptable contraception during  heterosexual activity. 
Acceptable methods of contraception  are**:  
• Single method (one of the following is  acceptable):  
 
▪ intrauterine device  (IUD)  
▪ vasectomy of a female subject’s sole male  partner  
▪ contraceptive rod implanted into the  skin 
• Combination method (requires use of two of the  following):  
▪ diaphragm with spermicide (cannot be used in conjunction with  
cervical cap/spermicide)  
▪ cervical cap with spermicide (nulliparous women  only)  
▪ contraceptive sponge (nulliparous women  only)  
▪ male condom or female condom (cannot be used  together)  
▪ hormonal contraceptive: oral contraceptive pi[INVESTIGATOR_4382] (estrogen/progestin pi[INVESTIGATOR_532730] - only pi[INVESTIGATOR_4382]), contraceptive skin p atch, vaginal contraceptive ring, or  
subcutaneous contraceptive  injection  
*Abstinence (relative to heterosexual activity) can be used as the sole method of contraception  
if it is consistently employed as the subject’s preferred and usual lifestyle and if  considered 
acceptable by [CONTACT_176742]/IRBs. Periodic abstinence (e.g.  calendar, 
ovulation, sympto -thermal, post -ovulation methods, etc.) and withdrawal are not  acceptable 
methods of  contraception.  
 
**If a contraceptive method listed a bove is restricted by [CONTACT_427]/guidelines, then it  
does not qualify as an acceptable method of contraception for subjects participating at sites in  
this country/region.  
 
Subjects should be informed that taking the study medication may involve unkn own risks to  
the fetus (unborn baby) if pregnancy were to occur during the study. In order to participate in  
the study, subjects of childbearing potential must adhere to the contraception requirement  
(described above) from the day of study medication initi ation (or 14 days prior to the initiation 
of trial treatment [Cycle 1 Day 1] for oral contraception) throughout the study period up to [ADDRESS_691756]’s status until the pregnancy has been completed or 
terminated.  The outcome of the pregnancy will be reported to the Sponsor -Investigator and to 
[COMPANY_006]  without delay and within 24 hours to the Sponsor -Investigator and within 2 working 
days to [COMPANY_006] if  the outcome is a serious adverse experience (e.g., death, abortion, congenital 
56 
 anomaly, or  other disabling or life -threatening complication to the mother or  newborn).  
 
The study investigator will make every effort to obtain permission to follow the outcome of  the 
pregnancy and report the condition of the fetus or newborn to the Sponsor. If a male  subject 
impregnates his female partner the study personnel at the site must b e informed immediately  
and the pregnancy reported to the  Sponsor -Investigator.  
 
8.2.[ADDRESS_691757] -feeding are not eligible for  
enrollment.  
 
8.6. Duration of Therapy  
In the absence of treatment delays due to adverse events, treatment may 
continue for up to  2 years (35 cycles of pembrolizumab) o r until one of the 
following criteria  applies:  
• Disease  progression  
• Intercurrent illness that prevents further administration of  treatment  
• Unacceptable adverse  events(s)  
• Patient decides to withdraw from the  study  
• General or specific changes in the patient's condition render the patient 
unacceptable  for further treatment in the judgment of the  investigator  
8.7. Duration of Follow Up  
Patients will be followed for [ADDRESS_691758]. Patients removed from study for 
unacceptable adverse events will  be followed until resolution or stabilization 
of the adverse  event..  
 
8.8. Criteria for Removal from Study  
Patients will be removed from study when any of the criteria listed in Section 6.5.1 
applies.  The reason for study removal and the date the patient was removed will be 
documented in the  Case Report  Form.  
 
 
9. DOSING DELAYS/DOSE  MODIFICATIONS  
 
9.1. Dose Modification for  Pembrolizumab  
 
Adverse events (both non-serious and serious) associated with pembrolizumab 
exposure  may represent an immunologic etiology. These adverse events may 
occur shortly after the first  dose or several months after the last dose of 
treatment. Pembrolizumab must be withheld for  drug- related toxicities and 
57 
 severe or life -threatening AEs as pe r Table 5  below. See Section 8.3.6  for 
supportive care guidelines, including use of  corticosteroids.  
 
 
Table 5 Dose Modification Guidelines for Pembrolizumab -Related Adverse Events  
 
 
Toxicity  Hold 
Treatment 
For Grade   
Timing for Restarting  Treatment   
Treatment  Discontinuation  
 
 
Diarrhea/Colitis  2-[ADDRESS_691759], ALT,  or 
Increased  Bilirubin  3-4 Permanently  discontinue 
(see exception  below)a Permanently  discontinue  
 
Toxicity  Hold 
Treatment 
For Grade   
Timing for Restarting  Treatment   
Treatment  Discontinuation  
Type 1  diabetes 
mellitus (if  new 
onset) or 
Hyperglycemia   
T1DM  or 
3-[ADDRESS_691760] dose or  inability 
to reduce  corticosteroid  to 10 mg or less of prednisone  or equivalent 
per day within 12  weeks  
4 Permanently  discontinue  Permanently  discontinue  
Note:  Permanently  discontinue  for any severe  or Grade  [ADDRESS_691761]  or ALT  increases  by [CONTACT_532786] 50% relative  to baseline 
and lasts for at least 1 week  then patients  should  be discontinued.  
b If symptoms  resolve  within  one hour of stoppi[INVESTIGATOR_64860],  the infusion  may be restarted  at 50% of the original  infusion  rate (e.g.,  from  100 mL/hr  to 50 
mL/hr).  Otherwise  dosing  will be held until symptoms  resolve  and the subject  should  be premedicated  for the next scheduled  dose;  Refer  to Table  4– Infusion 
Treatment  Guidelines  for further  management  details.  
c For grade  [ADDRESS_691762] dose.  
 
58 
 Dosing interruptions are permitted in the case of medical / surgical events or 
logistical  reasons not related to study therapy (e.g., elective surgery, unrelated 
medical events, patient  vacation, and/or holidays). Subjects should be placed 
back on study therapy within 3 weeks of  the scheduled interruption, unless 
otherwise discussed with the Sponsor. The reason for  interruption should be 
documented in the patient's study  record.  
 
9.2 Dose Modification for  Azacitidine  
If myelosuppression is present, subsequent treatment cycles of azacitidine 
should be  delayed until there is hematologic recover (ANC ≥ 1,000/μL, platelets 
≥ 50,000/μL). Following the  first cycl e of azacitidine treatment, if any of the 
following non -hematologic toxicities are  present, azacitidine treatment should 
not be restarted until the toxicity is resolved: 1) serum  bicarbonate level < 20 
mEq/L, 2) serum creatinine ≥ 2 mg/dL; 3) SGPT, total b ilirubin ≥ [ADDRESS_691763];  
4) 
and active or uncontrolled infection. Subjects will continue taking pembrolizumab 
on schedule  if toxicity is not related to this  agent.  
 
 
Table 6 Dose Levels for Trial Medications  
Drug  Starting  Dose  Dose Level  -1 Dose Level  -2 
Pembrolizumab  200 mg  fixed 
dose No dose 
reductions  are 
permitted  No dose 
reductions  are 
permitted  
Azacitidine  50 mg/m2  40 mg/m2  Discontinue  
 
 
10. ADVERSE EVENTS: LIST AND REPORTING  REQUIREMENTS  
 
10.1. Definition of an Overdose for this Protocol and Reporting of Overdose to  Sponsor - 
Investigator and to  [COMPANY_006]  
 
For purposes of this trial, an overdose  of: 
• pembrolizumab will be defined as any dose of 1,000 mg or greater (≥5 times  
the indicated  dose).  
• Azacitidine will be defined as any dose >/= 20% over the prescribed  dose.  
 
No specific information is available on the treatment of overdose of pembrolizumab. In the 
event of overdose, the subject should be observed closely for signs of toxicity. Appropriate  
supportive treatment should be provided if clinically  indicated.  
 
There is no known specific antidote for azacitidine overdosage. In the event of an overdose  
of azacitidine, the patient will be monitored with appropriate blood counts and will  receive 
supportive treatment as  necessary..  
 
59 
 If an adverse event(s) is associated with (“results from”) the overdose of a [COMPANY_006] product,  
the adverse event(s) is reported as a serious adverse event, even if no other seriousness 
criteria  are met.  
 
If a dose of [COMPANY_006]’s product meeting the protocol definition of overdose is taken without  any 
associated clinical symptoms or abnormal laboratory results, the overdose is reported as a  
non- serious Event of Clinical Interest (ECI), using the terminology “accidental or  intentional 
overdose without  adverse  effect.”  
 
All reports of overdose with and without an adverse event must be reported within 24 hours  
to the Sponsor -Investigator and within 2 working days hours to [COMPANY_006] Global Safety.  (Attn: 
Worldwide Product Safety; FAX 215  993-1220)  
 
10.2. Anticipate d Adverse Events  
 
Pembrolizumab : Refer to section  8.3.6  for specific adverse events related to  pembrolizumab.  
 
Azacitidine : The primary toxicities of azacitidine include bone marrow suppression, nausea  
and vomiting, diarrhea, constipation, injection site erythema, pyrexia, and  ecchymosis.  
 
10.3. Adverse Events Definitions:  
10.2.1  Adverse  Event:  
An adverse  event  (AE)  is any untoward  or unfavorable  medical  occurrence  in a human  subject, 
including abnormal sign, symptom or disease, temporally associated with the  subject’s 
participation  in research,  whether  or not considered  related  to the subject’s  participation  in 
the research.  Abnormal  results  of diagnostic  procedures  are considered  to be adverse  events  
if the abnormality:  
• results in study  withdrawal  
• is associated with a serious adverse  event  
• is associated with clinical signs or  symptoms  
• leads to additional treatment or to further diagnostic  tests 
• is considered by [CONTACT_137032]  
 
10.2.2  Serious Adverse  Event:  
A serious adverse event is any adverse event occurring at any dose or during any use of  the 
Sponsor’s product that  is: 
• fatal 
• life-threatening  
• requires inpatient hospi[INVESTIGATOR_059]/prolongatio n of existing hospi[INVESTIGATOR_059],  unless:  
o routine treatment or monitoring of the studied indication, not associated with  any 
deterioration in condition (procedures such as central line placements,  
paracentesis, pain  control)  
o elective or pre -planned treatment for a pre -existing condition that is unrelated to  
the indication under study and has not worsened since the start of study  drug 
o treatment on an emergency outpatient basis for an event not fulfilling any of  
the definitions of an SAE given above/below and not resulting in hospi[INVESTIGATOR_307]  
60 
 admissions  
o social reasons and respi[INVESTIGATOR_532731]’s general  condition  
• results in persistent or significant disability or  incapacity  
• a congenital anomaly or birth  defect  
• an important medical  event  
 
Important  medical  events  are those  that may not be immediately  life threatening,  but are clearly  
of major clinical significance. They may jeopardize the subject, and may require intervention  to 
prevent  one of the other  serious  outcomes  noted  above.  For example,  drug overdose  or abuse,  
a seizure that did not result in in -patient hospi[INVESTIGATOR_532732].  
 
All adverse events that do not meet any of the criteria for serious events should be regarded  
as non -serious adverse  events.  
 
Progression of the cancer under study is not considered an adverse  event.  
 
 
10.2.3  Unanticipated  Problem:  
An unanticipated problem is any incident, experience or outcome involving risks to subjects  or 
others in any human subjects research that meets all of the following  criteria:  
• Unexpected (in terms of nature, severity or frequency) given (a) the research  
procedures that are described in th e IRB -approval protocol and informed consent 
document, and (b)  the characteristics of the subject population being  studied;  
• Related or possibly related to participation in such research (e.g., there is a  reasonable 
possibility that the incident, experience  or outcome may have been caused by [CONTACT_532787]);  and 
• Suggests that the research places subjects or others at a greater risk of harm  
(including physical, psychological, economic or social harm) than was previously 
known  or recognized.  
10.4. Events of Clinical Interest  
Selected non -serious and serious adverse events are also known as Events of Clinical  Interest 
(ECI) and must be reported within 24 hours to the Sponsor -Investigator and within 2  working 
days to [COMPANY_006] Global Safety. ( Attn: Worldwide Product Safety; FAX 215  993-1220).  
 
For the time period beginning when the consent form is signed until  treatment 
allocation/randomization, any ECI, or follow up to an ECI, that occurs to any subject must  be 
reported within [ADDRESS_691764] to be excluded from the trial, or is the result of a  protocol -
specified intervention, including but not limited to washout or discontinuation of usual 
therapy,  diet, placebo treatment or a  procedure.  
For the time period beginning at treatment allocation/randomization through [ADDRESS_691765] for this trial  include:  
 
• An overdose of [COMPANY_006] product, as defined in Section 10.1 - Definition of an Overdose  
for This Protocol and Reporting of Overdose to the Sponsor -Investigator, that is  not 
associated with clinical  symptoms or abnormal laboratory  results.  
• An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit  of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X  the 
upper limit of normal and, at the same time, an alkaline phosphatase lab value that is  
less than 2X the upper limit of normal, as determined by [CONTACT_13149] -specified  
laboratory testing or unscheduled laboratory  testing.*  
 
• *Note: These criteria are based upon available regulatory guidan ce documents.  The 
purpose of the criteria is to specify a threshold of abnormal hepatic tests that may  
require an additional evaluation for an underlying  etiology.  
10.5. Adverse Event Reporting Period  
The study period during which adverse events must be reported is normally defined as the  
period from the initiation of any study procedures (e.g., after the first dose of study treatment) 
to the  end of the study treatment (e.g., last dose of study treatment) and/or follow -up. For this 
study,  the study treatm ent follow -up is defined as [ADDRESS_691766].  
 
10.2.4  Baseline/Preexisting  Condition  
A baseline/preexisting condition is one that is present at the start of the study. A  preexisting 
condition should be recorded as an adverse event if the frequency, intensity, or if the character  
of the condition worsens during the study  period.  
 
10.2.5  General Physical Examination  Findings  
At screening, any clinically significant abnormality should be recorded as a  preexisting 
condition. At the end of the study, any new clinically significant findings/abnormalities  that 
meet the definition of an adverse event must also be recorded a nd documented as an  adverse 
event.  
 
10.2.[ADDRESS_691767] to report any subsequent  
event(s) that the subject, or the subject’s personal physician, believes might reasonably be 
related  to participation in this  study.  
 
62 
 10.2.7  Abnormal Laboratory  Values  
A clinical laboratory abnormality should be documented as an adverse event if any one of  the 
following conditions is  met: 
• The laboratory abnormality is not otherwise refuted by a repeat test to confirm  
the abnormality  
• The abnormality suggests a disease and/o r organ  toxicity  
• The abnormality is of a degree that requires active management (e.g., change of  
dose, discontinuation of the drug, more frequent follow -up assessments, further  
diagnostic investigation,  etc.).  
10.2.8  Hospi[INVESTIGATOR_059], Prolonged Hospi[INVESTIGATOR_532733] a serious adverse event unless specifically instructed otherwise  in 
 
this protocol. Any condition responsible for surgery should be documented as an adverse  
event if the condition meets the criteria for an adverse  event.  
Neither the condition, hospi[INVESTIGATOR_059], prolonged hospi[INVESTIGATOR_059], nor surgery are reported as  an 
adverse event in the following  circumstances:  
• Hospi[INVESTIGATOR_532734] a preexisting condition. Surgery should not be reported as an outcome 
of an  adverse event if the purpose of the surgery was elective or diagnostic and the 
outco me was uneventful.  
• Hospi[INVESTIGATOR_532735].  
• Hospi[INVESTIGATOR_532736], unless it is a worsening or increase in frequency of hospi[INVESTIGATOR_532737].  
 
10.6. Assessing and Recording of Adverse Events  
An adverse event is defined as any untoward medical occurrence in a patient or  clinical 
investigation subject administered a pharmaceutical product and which does not necessarily  
have to have a causal relationship with this treatment. An adverse event can therefore be  any 
unfavorable and unintended sign (including an abnormal laboratory finding, for  example), 
symptom, or disease  temporally associated with the use of a medicinal product or  protocol - 
specified procedure, whether or not considered related to the medicinal product or  protocol - 
specified procedure. Any worsening (i.e., any clinically significant adverse change in  
frequency and/or intensity) of a preexisting condition that is temporally associated with the use 
of the [COMPANY_006]’s product, is also an adverse  event.  
 
All adverse events that occur after the consent form is signed but before  treatment 
allocation/randomization mu st be reported by [CONTACT_532788], or are the result of a protocol -specified intervention, including but  not 
limited to washout or discontinuation of usual therapy, diet, placebo treatment or a  proce dure.  
 
63 
 From the time of treatment allocation/randomization through [ADDRESS_691768] be reported by [CONTACT_093]. Such events will be  
recorded at each examination on the Adverse Event case report forms/wo rksheets. The  
reporting timeframe for adverse events meeting any serious criteria is described in section 
10.8.  The investigator will make every attempt to follow all subjects with non -serious adverse 
events  for outcome.  
 
Adverse events will not be collected for subjects during the pre -screening period  (for 
determination of archival tissue status) as long as that subject has not undergone any  
protocol - specified procedure or intervention. If the subject requires a blood draw, fresh 
tumor  biopsy, etc. , the subject is first required to provide consent to the main study and AEs 
will be  captured according to guidelines for standard AE  reporting.  
 
10.7. Evaluating Adverse Events  
An investigator who is a qualified physician will evaluate all adverse events accord ing to  the 
NCI Common Terminology for Adverse Events (CTCAE), version 4.0. Any adverse event  
which changes CTCAE grade over the course of a given epi[INVESTIGATOR_532738]/worksheets.  
 
All adverse events regardless of CTCAE grade must also be evaluated for  seriousne ss. 
Table 7 Evaluating Adverse Events  
V4.0  CTCAE  
Grading  Grade  1 Mild;  asymptomatic  or mid symptoms;  clinical  or diagnostic  observations  only;  
intervention  not indicated.  
 Grade  2 Moderate;  minimal,  local  or noninvasive  intervention  indicated;  limiting  age-
appropriate  instrumental  ADL.   Grade  3 Severe  or medically  significant  but not immediately  life-threatening;  
hospi[INVESTIGATOR_532739]; disabling; 
limiting self -care ADL.   Grade  4 Life threatening consequences; urgent intervention  indicated.  
 Grade  [ADDRESS_691769]  that: 
†Results in death ; or 
†Is life threatening;  or places  the subject,  in the view  of the investigator,  at immediate  risk of death  
from  the event  as it occurred  (Note:  This does not include  an adverse  event  that, had it occurred  in a 
more  severe  form,  might  have  caused  death.);  or †Results  in a persistent  or significant  disability/incapacity  (substantial  disruption  of one’s  ability  to 
conduct  normal  life functions);  or †Results  in or prolongs  an existing  inpatient  hospi[INVESTIGATOR_059]  (hospi[INVESTIGATOR_532740],  regardless  of length  of stay, even  if the hospi[INVESTIGATOR_144104] a precautionary  measure  for 
continued  observation.  (Note:  Hospi[INVESTIGATOR_532741] a pre-existing  condition  
that has not worsened  is not a serious  adverse  event.  A pre-existing  condition  is a clinical  condition  that 
is diagnosed  prior  to the use of a [COMPANY_006]  product  and is documented  in the patient’s medical history.);  or †Is a congenital  anomaly/birth  defect  (in offspring  of subject  taking  the product  regardless  of time to 
diagnosis);or  Is a new cancer  (that is not a condition  of the study)  (although  not serious  per ICH definition,  is 
reportable  to the Sponsor  within  24 hours  and to [COMPANY_006]  within  2 working days to meet certain local 
requirements);  or Is an overdose  (whether  accidental  or intentional).  Any adverse  event  associated  with an overdose  is 
considered  a serious  adverse  event  for collection  purposes.  An overdose  that is not associated  with an 
adverse  event  is considered  a non-serious  event  of clinical  interest  and must  be reported  within  [ADDRESS_691770]  and may require  medical  or surgical  intervention  to prevent  one of the 
outcomes listed previously (designated above by a  †). Duration  Record  the start and stop dates  of the adverse  event.  If less than [ADDRESS_691771]  to be discontinued?  
[ADDRESS_691772]  cause  the adverse  event?  The determination  of the likelihood  that [COMPANY_006]  product  
caused  the adverse  event  will be provided  by [CONTACT_532789] a qualified  physician.  The 
investigator’s  signed/dated  initials  on the source  document  or worksheet  that supports  the causality  noted  
on the AE form,  ensures that  a medically  qualified  assessment  of causality  was done.  This initialed  
document  must  be retained  for the required  regulatory  time frame.  The criteria  below  are intended  as 
reference  guidelines  to assist  the investigator  in assessing  the likelihood  of a relationship  between  the test 
drug and the adverse  event  based  upon  the available  information.  
The following  components  are to be used  to assess  the relationship  between  [COMPANY_006]  product  and the 
AE; the greater  the correlation  with the components  and their  respective  elements  (in number  and/or  
intensity),  the more  likely  [COMPANY_006]  product  caused  the adverse  event  (AE):  Exposure  Is there  evidence  that the subject  was actually  exposed  to [COMPANY_006]  product  such as: 
reliable  history,  acceptable  compliance  assessment  (pi[INVESTIGATOR_692], diary,  etc.),  expected  
pharmacologic  effect,  or measurement  of drug/metabolite  in bodily  specimen?  Time  Course  Did the AE follow  in a reasonable  temporal  sequence  from  administration  of [COMPANY_006]  
product?  
Is the time of onset  of the AE compatible  with a drug-induced  effect  (applies  to trials  with 
investigational  medicinal  product)?  Likely  Cause  Is the AE not reasonably  explained  by [CONTACT_532790],  other  
drug(s)/vaccine(s),  or other  host or environmental  factors   
 
46 
10.8. Reporting of Serious Adverse Events  
10.2.9  IRB Notification by  [CONTACT_2728] -Investigator  
Reports  of all events  (including  follow -up information)  that meet  the definition  of an 
unanticipated problem  posing  risk to subjects  or others  must  be submitted  to the IRB within  one 
week  (5 business days) following the occurrence of the unanticipated problem or the principal  
investigator’s acquiring knowledge of the unanticipated problem in accordance with IRB policy.  
Additionally, the sponsor -investigator will submit a sum mary of all Unanticipated problems that 
occurred  since the beginning of the study at the time of continuing review. Copi[INVESTIGATOR_532742].  
 
10.2.[ADDRESS_691773] report to the FDA and  any 
affiliate site investigators as  follows:  
 
• Any unexpected fatal or life -threatening event must be reported as soon as possible,  
but no later than 7 calendar days after the sponsor investigator initial receipt of  the 
information  
• Any findings from epi[INVESTIGATOR_9037], pooled analysis of  multiple 
studies, or clinical studies, whether or not conducted under an IND,  and 
whether or not conducted by [CONTACT_456] -investigator, that sugge st a 
significant risk in humans exposed to the drug must be reported as soon  
as possible but no later than 15 calendar days after the  sponsor -
investigator determines that the information qualifies for  reporting  
• Any findings from animal or in vitro testing whether or not conducted  
[ADDRESS_691774] igator determines that the information qualifies for  
reporting  
• Any clinically important increase in the rate of a serious suspected  
adverse reactions over that listed in the protocol or Investigator  
Brochure  
• Expected SAEs and AEs will be included in the IND Annual  Reports.  
 
Follow -up information to a safety report should be submitted as soon as the relevant  
information is available. However, if the results of a sponsor’s investigation show that an 
adverse  drug experience not initially determined to be rep ortable are so reportable, the sponsor  
investigator  
 
[ADDRESS_691775] as described in  section  
10.8.1 and/or to the FDA as described in section 10.8.2 within 72 hours of 
becoming aware of  it, so that these reports can be evaluated and included in the 
Investigator’s Brochure and for  IND safety submissions per regulations. 
Reporting will occur by [CONTACT_532791].  
 
At the time of IRB renewal or at the request of the manufacturer, the Sponsor - 
Investigator  will submit a summary of all Serious Adverse Events that have 
occurred inclusive of all sites  to manufacturer.  
 
10.[ADDRESS_691776] Name &  Potency  Dosage  Form  Additional  Information  
Pembrolizumab 50  mg/vial  Lyophilized powder  for 
injection  Provided centrally by  [CONTACT_532792] [ADDRESS_691777] not included in Table 8 (i.e. azacitidine) will 
be provided  by [CONTACT_21655], subsidiary or design ee. Every attempt should be made 
to source these supplies  from a single lot/batch  number.  
 
The trial site is responsible to record the lot number, manufacturer and expi[INVESTIGATOR_532743].  
 
11.2. Packing and Labeling Information  
Clinical supplies will be affixed with a clinical label in accordance with 
regulatory  requirements. Subjects will receive open label vials and/or kits for 
every 3 -week  dosing.  
 
11.3. Clinical Supplies Disclosure  
This trial is open -label; therefore, the subject, the trial site personnel, the 
Sponsor  and/or designee are not blinded. Treatment (name, strength or potency) 
67 
 is included in the label  text; random code/disclosure envelopes or lists are not 
provided.  
 
11.4. Storage and Handling Requirements  
Clinical supplies must be stored in a secure, limited -access location under the 
storage  conditions specified on the label. Receipt and dispensing of trial 
medication must be recorded by  [CONTACT_131895]. Clinical 
supplies may not be used for any purpose other  than that stated in the  protocol.  
 
11.5. Discard/Destruction/Returns and Reconciliation  
The investigator is responsible for keepi[INVESTIGATOR_532744], the amount dispensed to and 
returned by [CONTACT_532793]. 
For all trial sites, the local country Sponsor personnel  or designee will provide 
appropriate document ation that must be completed for drug  accountability and 
return, or local discard and destruction if appropriate. Where local discard and 
destruction  is appropriate, the investigator is responsible for ensuring that a local 
discard/destruction  procedure is documented.  
 
11.6. Standard Policies  
Trial site personnel will have access to a central electronic randomization system  
(IVRS/IWRS system) to allocate subjects, to assign treatment to subjects and to 
manage the distribution  of clinical supplies. Each person a ccessing the IVRS 
system must be assigned an individual  unique PIN. They must use only their 
assigned PIN to access the system, and they must not share  their assigned PIN 
with anyone.  
 
11.7. Other Agent: Azacitidine  
Product description : Azacitidine (Vidaza) at a  dose of 50 mg/m2 by [CONTACT_532794] 5 days. Repeat cycle after 4  weeks.  
 
Solution preparation (how the dose is to be prepared): Azacitidine should be  
aseptically reconstituted with 4 mL of Sterile Water for Injection (USP); upon 
reconstitution, the  resulting suspension will contain azacitidine 25 mg/mL. The 
reconstituted product may be kept in the  vial or drawn into a syringe. Doses 
greater than 4 mL should be divided equally into 2  syringes.  
 
Storage requirements : The reconstitut ed product may be held at room 
temperature for up to  [ADDRESS_691778] may be 
held under refrigerated conditions (2 °C – 8°C, 36 °F – 46°F) for up to 8 hours.  
When azacitidine is reconstituted using refrigerated (2 °C – 8°C, 36 °F – 46°F) 
water for injection,  the reconstituted product may be stored under refrigerated 
68 
 conditions (2 °C – 8°C, 36 °F – 46°F) for up to 22 hours. After removal from 
refrigerated conditions, the suspension may be allowed  to equilibrate to room 
temperature for up to 3 0 minutes prior to  administration.  
 
Stability : Azacitidine reconstituted with non -refrigerated water for injection for  
SubQ administration may be stored for up to 1 hour at 25 °C (77 °F) or for up to 8 
hours between  2°C and 8 °C (36 °F and 46 °F); when reconsti tuted with 
refrigerated (2 °C – 8°C, 36 °F – 46°F) water for injection, it may be stored for 22 
hours between 2 °C and 8 °C (36 °F and  46°F). 
 
Route of administration: Azacitidine is administered at a dose of 50 mg/m2 by 
[CONTACT_532795], rotating sites for each injection (thigh, abdomen, or upper arm), 
repeated daily for [ADDRESS_691779] followed by [CONTACT_192656].  
 
 
12. STUDY  CALENDAR  
 
12.1. Trial Flow Chart  
 
Baseline evaluations are to be conducted according to the trial flow chart below 
(Sect ion 12.1). Scans and x -rays must be done < 4 weeks prior to the start of 
therapy. In the event that  the patient’s condition is deteriorating, laboratory 
evaluations should be repeated within 48  hours prior to initiation of the next 
cycle of  therapy.  
 
  
 
 
 
Trial  Period:   
 
 
Screening  Phase  Treatment Cycles  a End of 
Treatment  (last 
dose)  or 
Discontinuatio
n  
 
 
Post-Treatment  Azacitidine (4 weeks per  cycle)  Pembrolizumab (3 weeks  per 
cycle)  
 
Treatment  Week:   1 2 3 5 6 8 9 12 15 18 Safety 
Follow - Up 
([ADDRESS_691780] dose)q  
Follow  Up 
Visitsb (Q8W)  Survival 
Follow -
Up 
(Phone)   
 
Scheduling Window  (Days):   
 
-28 to  -1   
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3 
± 7 
Administrative  Procedures  
Informed Consent  c X               
Inclusion/Exclusion  Criteria  X               
Demographics and Medical  History  X               
Prior and Concomitant  Medication 
Review  X X  X X X  X X X X X X   
Clinical  Procedures/Assessments  
Review Adverse  Events  X   X X X  X X X X X    
12-Lead  ECG  X               
Physical  Examination  X X  X X X  X X X X X    
Ht (V1 only), Wt, & Vital  Signs 
(T/P/RR/BP)  X           X    
ECOG Performance  Status  Xp X  X X X  X X X X X    
Azacitidine  Treatment 
Administrationo  X   X   X then  Q4W         
Pembrolizumab  Treatment 
Administrationo    X  X  X then  Q3W         
Post-study Anticancer  Therapy 
Status               X Q12W  
Survival  Status                Q12W  
Laboratory  Procedures/Assessments:  analysis  performed  by [CONTACT_532796] – Urine or Serum  
- HCGd X               
PT/INR and  aPTTe X               
CBC with  Differentiale,g X X  X X X  X X X X X X   
Chemistry  Panele,f X X  X X X  X X X X X X   
Urinalysise X               
Amylase and  Lipase  X     X  X    X    
 
 
 51 
Trial  Period:  Screening  Phase  Treatment Cycles  a End of 
Treatment  (last 
dose)  or 
Discontinuatio
n Post-Treatment  Azacitidine (4 weeks per  cycle)  Pembrolizumab (3 weeks  per 
cycle)  
 
Treatment  Week:   1 2 3 5 6 8 9 12 15 18 Safety 
Follow - Up 
([ADDRESS_691781] dose)   
Follow  Up 
Visitsb (Q8W)  Survival 
Follow -
Up 
(Phone)   
 
Scheduling Window  (Days):   
 
-28 to  -1   
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3 
± 7 
T3, FT4 and TSHe X   X  X  X then  Q6W     X X   
 
Serum CA  19-9e,h  
X    
X   
X   
X  X 
then 
Q6W    
X    
HBV, HCV,  HIVe,i X               
Efficacy  Measurements  
Tumor  Imaging   
Xj      Xk then 
Q8W       
Xl    
Tumor  Biopsies/Archival  Tissue  Collection/Correlative  Studies  Blood  
Archival or Newly Obtained  Tissue 
Collectionm X      X     Xoptional     
Correlative Studies  Blood 
Collection  Xn    
X  
X  
X      X    
a. Unless  otherwise  specified,  assessment/procedures  are to be performed  prior  to dose administration  on Day 1 of each cycle.  
b. Subjects  who discontinue  study  treatment  without  documented  disease  progression  should  continue  to be monitored  for disease  by [CONTACT_532797]  8 weeks  (
7 days)  until (1) the start of new anti-cancer 
treatment,  (2) disease  progression,  (3) death,  or (4) the end of the study,  whichever  occurs  first. 
c. Informed  consent  will include  consent  for correlative  studies  including  biopsies  and serum  collections.  
d. For women  of reproductive  potential,  a negative  pregnancy  test should  be performed  within  [ADDRESS_691782] dose of trial treatment.  Pregnancy  tests (serum  and/or  urine  tests)  should  be repeated  if required  by [CONTACT_259138].  
e. Laboratory  Screening  Tests  should  be performed  within  [ADDRESS_691783] dose lab may 
be collected  up to 72 hours  prior  to the scheduled  timepoint.  
f. Chemistry  will be collected  on Day 1 of each cycle  of azacitidine  and pembrolizumab.  
g. CBC  with differentials  will be collected  on Day 1 of each cycle  of azacitidine  and pembrolizumab.  
h. On treatment  CA 19-9 – starting  at Cycle  1 of Pembrolizumab,  CA 19-9 will be collected Q3W  until week  15 then every  2 pembrolizumab  cycles  (Q6W  +/- 2 weeks)  through  the end of treatment  
i. All subjects  will be tested  for HIV, HBV,  and HCV  prior  to enrollment.  Those  who are positive  for HIV,  untreated  active  Hepatitis  B, and dual infection  with HBV/HCV  will be excluded.  
j. Tumor  imaging  at screening:  Imaging  will be performed  within  [ADDRESS_691784]-on study  tumor  imaging  will be performed  after 8 weeks  (7 days)  of treatment,  and will continue  every  8 weeks  (
7 days)  thereafter  (or more  frequently  if clinically  indicated).  Timing  of imaging  follows 
calendar  days and should  not be adjusted  due to dose interruptions.  The same  imaging  technique,  acquisition,  and processing  parameters  for a subject  should  be used throughout  the trial if possible.  
l. Subjects  without  confirmed  PD who discontinue  treatment  will have  imaging  performed  at the time study  treatment  is discontinued  (i.e. date of discontinuation  
4 week  window). If  a scan was obtained  within  [ADDRESS_691785]  a newly -obtained 
biopsy during week 8 (
 7 days) of the study. An optional biopsy is also requested at the time of discontinuation for PD. 
 
 Trial  Period:  Screening  Phase  Treatment Cycles  a End of 
Treatment  (last 
dose)  or 
Discontinuation  Post-Treatment  Azacitidine (4 weeks per  cycle)  Pembrolizumab (3 weeks  per 
cycle)  
 
Treatment  Week:   1 2 3 5 6 8 9 12 15 18  Safety 
Follow - Up 
([ADDRESS_691786]  
dose)q  
Follow  Up 
Visitsb (Q8W)  Survival 
Follow -Up 
(Phone)   
 
Scheduling Window  (Days):   
 
-28 to  -1   
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3  
 
± 3 
± [ADDRESS_691787]   at baseline, and then on week s 3, 5, and 6 prior to study treatment administration. Whole  blood  for Genetics/RNA  and DNA  analyses.  Serum  and plasma  for Proteomics.  
o. The first dose of azacitidine  is Week  [ADDRESS_691788]  a +/-3 day window  for dose administrations  (for azacitidine  as well as pembrolizumab).  Azacitidine will be dosed on [ADDRESS_691789]. 
 
72 
 12.2. Trial Procedures  
 
The Trial Flow Chart - Section  12.1 summarizes the trial procedures to be performed at  each 
visit. Individual trial procedures are described in detail below. It may be necessary to  perform 
these procedures at unscheduled time points if deemed clinically nece ssary by [CONTACT_11168]. 
Furthermore, additional evaluations/testing may be deemed necessary by [CONTACT_112102]/or 
[COMPANY_006] for reasons related to subject safety. In some cases, such evaluation/testing may  be 
potentially sensitive in nature (e.g., HIV, Hepa titis C, etc.), and thus local regulations  may 
require that additional informed consent be obtained from the subject. In these cases,  such 
evaluations/testing will be performed in accordance with those  regulations.  
 
12.3. Administrative Procedures  
12.1.[ADDRESS_691790]’s 
legally acceptable representative prior to participating in a clinical  trial. 
 
Consent must be documented by [CONTACT_423]’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s  legally 
acceptable representative’s dated signature [INVESTIGATOR_2394] a consent form along with the dated signature  
[CONTACT_63564]. A copy of the signed and dated consent  form 
should be given to the subject before participation in the  trial. 
 
The initial informed consent form, any subsequent revised written informed consent form  and 
any written information provided to the subject must receive the IRB/ERC’s  approval/  favorable 
opi[INVESTIGATOR_19349]. The subject or his/her lega lly acceptable representative should  be 
informed in a timely manner if new information becomes available that may be relevant to  the 
subject’s willingness to continue participation in the trial. The communication of  this 
information will be provided and documented via a revised consent form or addendum to  the 
original consent form that captures the subject’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s  legally 
acceptable representative’s dated  signature.  
 
The informed consent will adhere to IRB/ERC re quirements, applicable state laws and  federal 
regulations.  
 
12.1.2  Inclusion/Exclusion  Criteria  
All inclusion and exclusion criteria will be reviewed by [CONTACT_532798]. 
 
12.1.[ADDRESS_691791] has enrolled in this study will be recorded separately and not listed as medical  history.  
 
12.1.4  Prior and Concomitant  Medications  
[IP_ADDRESS]  Prior  Medications  
The investigator or qualified designee will review prior medication use, including any  protocol - 
 
[ADDRESS_691792] has enrolled in this  
study will be recorded separately and not listed as a prior  medication.  
 
[IP_ADDRESS]  Concomitant  Medications  
The investigator or qualified designee will record medication, if any, taken by [CONTACT_532799].  All medications related to reportable SAEs and ECIs sh ould be  recorded.  
 
12.1.5  Disease Details and  Treatments  
[IP_ADDRESS]  Disease  Details  
The investigator or qualified designee will obtain prior and current details regarding  disease 
status.  
 
[IP_ADDRESS]  Prior Treatment  Details  
The investigator or qualified designee will review all prior cancer treatments including  systemic 
treatments, radiation and  surgeries.  
 
[IP_ADDRESS]  Subsequent Anti -Cancer Therapy  Status  
The investigator  or qualified  designee  will review  all new anti-neoplastic  therapy  initiated  after 
the last dose of trial treatment. If a subject initiates a new anti -cancer therapy within [ADDRESS_691793]  will move  into 
survival  follow -up. 
 
12.1.6  Clinical  Procedures/Assessments  
[IP_ADDRESS]  Adverse Event (AE)  Monitoring  
The investigator or qualified designee will assess each subject to evaluate for potential new  or 
worsening AEs as specified in the Trial Flow Chart and more frequently if clinically  indicated. 
Adverse experiences will be graded and recorded throughout the study and during the  follow -up 
period according to NCI CTCAE Ve rsion 4.0. Toxicities will be characterized in terms  
regarding seriousness, causality, toxicity grading, and action taken with regard to trial  treatment.  
 
Refer to Section 10 for detailed information regarding the assessment and recording of  adverse 
events.  
 
[IP_ADDRESS]  Physical  Exam  
The investigator or qualified designee will perform a complete physical exam during  the 
screening period. Clinically significa nt abnormal findings should be recorded as medical  
history. A physical exam should be performed as specified in the Trial Flow Chart (Section 
12.1) . For subsequent cycles the investigator or qualified designee will perform a directed 
physical exam  as clinically indicated prior to dosing on Day [ADDRESS_691794] dose of  trial treatment new clinically significant abnormal findings should be recorded as  
AEs.  
 
[IP_ADDRESS]  Vital Signs  
The investigator or qualified desi gnee will take vital signs at screening, prior to  the 
74 
 administration of each dose of trial treatment and at treatment discontinuation as specified in  
the 
 
Trial Flow Chart (Section 12.1). Vital signs should include temperature, pulse, respi[INVESTIGATOR_2842], 
weight and blood pressure. Height will be measured at screening  only.  
 
[IP_ADDRESS]  Eastern Cooperative Oncology Group (ECOG) Performance  Status 
The investigator  or qualified  designee  will assess  ECOG  status  (see Appendix  1) at 
screening, prior to the administration of each dose of trial treatment and discontinuation of trial 
treatment  as specified in the Trial Flow  Chart.  
 
[IP_ADDRESS]  Tumor Imaging and Assessment of  Disease  
CT chest, abdomen, and pelvis with contrast will be performed at baseline screening, prior to  
the administration of study drugs, and every 8 weeks  thereafter.  
 
[IP_ADDRESS]  Tumor Tissue Collection and Correlative Studies Blood  
Sampling  
All patients will have tumor biopsy specimens obtained at baseline prior to study  drug 
administration and then during week 8 to assess methylation status and immune  response. 
Peripheral blood will be evaluated for methylation status at basel ine and then prior to treatment 
administration on weeks 3, 5, and 6.  
 
[IP_ADDRESS]  Laboratory  Procedures/Assessments  
Details regarding specific laboratory procedures/assessments to be performed in this trial  are 
provided below. Laboratory tests for hematology, chemistry, urinalysis, and others are  specified 
in the Trial Flow Chart (Section  12.1). 
 
Laboratory tests for screening should be performed within [ADDRESS_691795] – Solid  Tumors  
For the purposes of this study, patients should be re -evaluated for response every 8 weeks.  In 
addition to a baseline scan, confirmatory scans should also be obtained 8 (not less than 4)  weeks 
following initial documentation of objective  response.  
 
Response and progression will be evaluated in this study using the new international  criteria 
proposed by [CONTACT_459] (RECIST)  guideline 
(version 1.1)74. Changes in the largest diameter (unidimensional measurement) of the  tumor 
lesions and the shortest diameter in the case of malignant lymph nodes are used in the  RECIST 
criteria.  
 
75 
 13.1.1  Definitions of evaluable  subjects  
Evaluable for toxicity : All patients will be evaluable for toxicity from the time of their  first 
treatment with  azacitidine.  
 
Evaluable for DLT assessment: The initial [ADDRESS_691796] 1 cycles (5 doses)  of 
 
azacitidine and 1 dose of pembrolizumab will be evaluated for DLT. Subjects who do  not 
complete these doses will be  replaced.  
 
Evaluable for PFS - primary outcome: All subjects who receive a single dose of  pembrolizumab 
will be included in the primary outcome analysis of PFS. If subjects are removed from  study 
prior to completing a single dose of pembrolizumab, they will be  replaced.  
 
Evaluable for objective response: Only those patients who have measurable disease present  at 
baseline, have received at least one cycle of therapy, and have had their disease re -evaluated  
will be considered evaluable for response.  These patients will have their response  classified 
according to the definitions stated below. (Note: Patients who exhibit objective  disease 
progression prior to th e end of cycle 1 will also be considered  evaluable.)  
 
13.2. Disease Parameters  
Measurable disease : Measurable lesions are defined as those that can be accurately measured  in 
at least one dimension (longest diameter to be recorded for non -nodal lesions and short axis for 
nodal lesions) as >[ADDRESS_691797] x -ray, as >[ADDRESS_691798] scan, or >[ADDRESS_691799] be recorded in millimeters (or decimal fractions  of 
centimeters). Tumor lesions that are situated in a previousl y irradiated area are not  considered 
measurable.  
 
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a  lymph 
node must be >[ADDRESS_691800] scan (CT scan slice  thickness 
recommended to be no greater than 5 mm). At baseline and in follow -up, only the short axis  
will be measured and  followed.  
 
Non-measurable disease : All other lesions (or sites of disease), including small lesions  (longest 
diameter <10 mm or pathological lymph nodes with ≥ 10 to  <15 mm short axis), are  considered 
non-measurable disease. Bone lesions, leptomeningeal disease, ascites,  pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal  masses 
(not followed by [CONTACT_462]), are cons idered as  non-measurable.  
 
Note: Cystic lesions that meet the criteria for radiographically defined simple cysts should  not 
be considered as malignant lesions (neither measurable nor non -measurable) since they are,  by 
[CONTACT_108], simple cysts. Cystic lesio ns thought to represent cystic metastases can be  considered 
as measurable lesions, if they meet the definition of measurability described above. However,  if 
non-cystic lesions are present in the same patient, these are preferred for selection as  target 
lesions. 
 
Target lesions: All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions  in 
76 
 total, representative of all involved organs, should be identified as target lesions and  recorded 
and measured at baseline. Target lesions should be selected on the basis of their size  (lesions 
with the longest diameter), be representative of all involved organs, but in addition should  be 
those that lend themselves to reproducible repeated measurements. It may be the case that,  on 
occasion, the largest  lesion does not lend itself to reproducible measurement in  which  
 
circumstance the next largest lesion which can be measured reproducibly should be selected.  A 
sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all  target 
lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to  be 
included in the sum, then only the short axis is added into the sum. The baseline sum  diameters 
will be used as reference to further characterize any objecti ve tumor regression in the  
measurable dimension of the  disease.  
 
Non-target lesions : All other lesions (or sites of disease) including any measurable lesions  over 
and above the [ADDRESS_691801] and MRI: This guideline has defined measurability of lesions on CT sca n 
based on the assumption that CT slice thickness is [ADDRESS_691802] slice  
thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice  
thickness. MRI is also acceptable in certain situations (e.g., for bo dy scans).  
 
Use of MRI remains a complex issue. MRI has excellent contrast, spatial, and  temporal 
resolution; however, there are many image acquisition variables involved in MRI, which  greatly 
impact image quality, lesion conspi[INVESTIGATOR_3934], and measurement.  Furthermore, the availability  of 
MRI is variable globally. As with CT, if an MRI is performed, the technical specifications of  the 
scanning sequences used should be optimized for the evaluation of the type and site of  disease. 
Furthermore, as with CT, the modality used at follow -up should be the same as was used  at 
baseline and the lesions should be measured/assessed on the same pulse sequence. It is  beyond 
the scope of the RECIST guidelines to prescribe specific MRI pulse seque nce parameters for  all 
scanners, body parts, and diseases. Ideally, the same type of scanner should be used and  the 
image acquisition protocol should be followed as closely as possible to prior scans. Body  scans 
should be performed with breath -hold scannin g techniques, if  possible.  
 
Tumor markers: Tumor markers alone cannot be used to assess response. If markers are  initially 
above the upper normal limit, they must normalize for a patient to be considered in  complete 
clinical  response.  
[ADDRESS_691803] Criteria  
13.4.1  Evaluation of Target  Lesions  
Complete Response (CR) : Disappearance of all target lesions. Any pathological lymph  nodes 
(whether target or non -target) must have reduction in short axis to <10  mm. 
 
Partial Response (PR) : At least a 30% decrease in the sum of the diameters of target  lesions, 
taking as reference the baseline sum  diameters.  
 
Progressive Disease (PD) : At least a 20% increase in the sum of the diameters of target  lesions, 
taking as reference the smallest sum on study (this in cludes the baseline sum if that is  the 
smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate  an 
absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is  also 
considered  progressions).  
 
Stable Disease (SD) : Neither sufficient shrinkage to qualify for PR nor sufficient increase  to 
qualify for PD, taking as reference the smallest sum diameters while on  study.  
 
13.4.2  Evaluation of Non -Target  Lesions  
Complete Response (CR) : Disappearance of all n on-target lesions and normalization of  tumor 
marker level.  All lymph nodes must be non -pathological in size (<10 mm short  axis).  
 
Note: If tumor markers are initially above the upper normal limit, they must normalize for  a 
patient to be considered in complete clinical  response.  
 
Non-CR/Non -PD: Persistence of one or more non -target lesion(s) and/or maintenance of  tumor 
marker level above the normal  limits.  
 
Progressive Disease (PD) : Appearance of one or more new lesions and/or  unequivocal 
progression of existing non -target lesions. Unequivocal progression should not normally  trump 
target lesion status. It must be representative of overall disease status change, not a single  lesion 
increase. Although a clear progression of “non -target” lesions only is exceptional, the opi[INVESTIGATOR_532745], and the progression status should  be 
confirmed at a later time by [CONTACT_463] (or Principal  Investigator).  
 
13.4.[ADDRESS_691804] response recorded from the start of the treatment  until 
disease progression/recurrence (taking as reference for progressive disease the  smallest 
measurements recorded since the treatment started). The patien t's best response assignment  will 
depend on the achievement of both measurement and confirmation  criteria.  
 
 
[ADDRESS_691805] Overall 
Response  when 
Confirmation  is 
Required*  
CR CR No CR >4 wks. 
Confirmation**  
CR Non-CR/Non -PD No PR  
>4 wks. 
Confirmation**  CR Not evaluated  No PR 
PR Non-CR/Non - 
PD/not  evaluated  No PR 
SD Non-CR/Non - 
PD/not  evaluated  No SD documented at  least 
once >4 wks.  from 
baseline**  
PD Any Yes or 
No PD  
 
no prior SD, PR or  CR Any PD***  Yes or 
No PD 
Any Any Yes PD 
* See RECIST 1.1 manuscript for further details on what is evidence of a new  lesion.  
** Only for non-randomized trials with response as primary  endpoint.  
*** In exceptional circumstances, unequivocal progression in non -target lesions may  be 
accepted as disease  progression.  
 
Note : Patients with a global deterioration of health status requiring discontinuation  of 
treatment without objective evidence of disease progression at that time should be  reported 
as “symptomatic deterioration.” Every effort should be made to document the  objective 
progression even after discontinuation of  treatment.  
 
 
13.5. Assessment of Disease According to Immune Related RECIST for Solid  Tumors  
Although this will not be the primary endpoint we will allow subjects to remain on study if  they 
meet the criteria for immune related RECIST as described. The immune related  RECIST 
(irRECIST), is adapted to account for the unique tumor response seen with  immunotherapi[INVESTIGATOR_014].[ADDRESS_691806] criteria considers index lesions identified at baseline together with new  lesions 
that may occur after the star t of treatment and are incorporated into the calculated tumor  burden. 
The appearance of new lesions alone does not constitute  PD. 
 
If imaging shows PD, tumor assessment should be repeated 4 weeks later to confirm PD with  
the option of continuing treatment for clinically stable subjects. Clinically stable will be defined  
by [CONTACT_144134]:  
• Absence of signs and symptoms indicating disease  progression  
• No decline in ECOG performance  status  
79 
 • Absence of rapid progression of  disease  
• Absence of progressive tumor at critical anatomical sites (eg, cord  compression) 
requiring urgent alternative medical  intervention  
• Absence of disease progression in close proximity to a vital  organ.  
 
Subjects must meet the above bulleted criteria for clinically stabl e disease in order to  continue 
on study treatment beyond initial imaging showing PD. Clinically stable subjects who  continue 
on study treatment will first be  reconsented.  
In determining whether the tumor burden has increased or decreased, investigators  should 
consider all target lesions as well as non -target lesions. Subjects who are deemed  clinically 
unstable are not required to have repeat imaging for confirmation. If radiologic progression  is 
confirmed, then the subject will be discontin ued from study treatment as specified in  the 
Protocol, and the first radiographic evidence of PD should be the date of progression.  If 
radiologic progression is not confirmed, then the subject should resume/ continue  study 
treatment and have their next sca n according to the Protocol -specified schedule (ie 4 weeks  later 
and then every 8 weeks). If progression is not confirmed and the subject continues on  treatment, 
the next scan that documents disease progression (and is confirmed by a second scan at least  4 
weeks later) will be considered the  date 
of disease  progression.  
 
NOTE: If a subject with confirmed radiographic progression (ie, [ADDRESS_691807] 28 days  apart 
demonstrating PD) is clinically stable or clinically improved, and there is no further increas e in 
the tumor dimensions at the confirmatory scan, an exception may be considered to continue  
treatment upon consultation with the sponsor. In order for a patient to be considered clinically 
stable,  all bulleted criteria listed above in section 13.[ADDRESS_691808] at the confirmatory scan no further increase in the target lesions, no  
unequivocal increase in non -target lesions, and no additional new lesions develop (non -
worsening PD)  to continue study treatment. Such exceptions will need to be made in 
consultation with the  study Sponsor and the trial’s DSMC. However, study treatment continued 
beyond PD will  be discontinued if radiologic progression  worsens.  
 
13.5.[ADDRESS_691809]  
Tumor burden = Sum of diameter (target) + Sum of diameter  (new)  
 
Complete Response (CR) : Disappearance of all target lesions. Any pathological lymph  nodes 
(whether target or non -target) must have reduction in short axis to <10  mm. 
 
Partial Response (PR) : At least a 30% decrease in the tumor burden compared with  baseline.  
 
Progressive Disease (PD) : At least a 20% increase in the tumor burden compared, taking  as 
reference the smallest sum on study (this includes the baseline sum if that is the  smallest  on 
study), with confirmation of progression by a scan at least 4 weeks later (Note: With  
irRECIST, the appearance of new lesions alone is not considered  progression).  
 
Stable Disease (SD) : Neither sufficient shrinkage to qualify for PR nor suffic ient increase  to 
[ADDRESS_691810] response recorded from the start of the treatment  until 
disease progres sion/recurrence (taking as reference for progressive disease the  smallest 
measurements recorded since the treatment started). The patient's best response assignment  
will depend on the achievement of both measurement and confirmation  criteria.  
 
Measurable 
Response  Nonmeasurable  Response  Overall  Response  
Total  Measurable 
Tumor  Burden  Non-Index  Lesions  New  Nonmeasurable 
Lesions  Using  irRECIST  
100%  Decrease  Absent  Absent  irCR  
≥ 30%  Decrease  Any Any irPR 
<30% Decrease  to 
<20%  Increase  Any Any irSD  
≤ 20%  Increase  Any Any irPD  
 
 
13.6. Analysis of Endpoints  
Efficacy and safety endpoints that will be evaluated are listed  below.  
 
13.6.1  Efficacy  Endpoints  
[IP_ADDRESS]  Primary Efficacy  Endpoint  
▪ Progression -Free Survival  
o PFS is defined as the time from the first day of trial treatment to the  first 
documented disease progression per RECIST 1.[ADDRESS_691811]. 
 
[IP_ADDRESS]  Secondary Efficacy  Endpoints  
▪ Objective Response  Rate 
o ORR is defined as the proportion of the subjects in the analysis population  who 
have a CR or PR. Responses are based on assessments per RECIST  1.1. 
▪ Duration of  Response  
o For subjects who demonstrate CR or PR, based on assessments per RECIST  1.1, 
DOR is defined as the time from first documented evidence of CR or PR  until 
disease progression or death due to any cause, whichever occurs  first. 
▪ Disease Control  Rate 
o DCR is defined as the percentage of subjects who have achieved CR, PR, or  SD 
based on assessments per RECIST  1.1. 
• Overall Survival  (OS)  
o OS is defined as the time from first dose of study medication to death due to  any 
cause.  
 
13.6.[ADDRESS_691812] rece ived pembrolizumab, including serious  
adverse events (SAEs) and events of clinical interest  (ECIs).  
 
Safety will be assessed by [CONTACT_193439], Version 4.0.  The 
attribution to study treatment, time -of-onset, duration of the event,  its resolution, and  any 
concomitant medications administered will be recorded. AEs will be analyzed including but  not 
limited to all AEs, SAEs, fatal AEs, and laboratory changes. Furthermore, specific  immune - 
related adverse events (irAEs) will be collected and designated as immune -related events  of 
clinical interest (ECIs) as described in Section  10.4. 
 
13.6.3  Correlative  Endpoints  
[IP_ADDRESS]  Global DNA  Methylation  
DNA methy lation, using LINE -[ADDRESS_691813] eight 
weeks of the study. Disease control rates (DCR) and time to event endpoints (PFS and OS)  will 
 
be estimated for patients who have methylation below the median compared to above the  
median at baseline. We will also estimate these outcomes for th ose who achieve low 
methylation  (<10% methylation) compared to normal methylation (≥10% methylation) after 
eight weeks of  therapy. We will also estimate these outcomes for those who achieve a change in 
methylation greater  than the median compared to lower than the median at eight weeks 
compared to  baseline.  
 
 
[IP_ADDRESS]  Epi[INVESTIGATOR_532746]/or stromal cells results  
in a significant polarization of the immune response seen in pancreatic  cancer and this leads to  
an increase in response to tumor checkpoint inhibition.  Our preliminary data provides  strong 
support for this, however this study provides a unique opportunity to understand the  dynamic 
changes that occur in the tumor. Therefore we will first assess the impact of the  systemically 
administered demethylating agent on tumor tissue. This assessment is performed in all  31 
patients 8 weeks after completion of TCI therapy. Core biopsies are obtained and tumor tissue  is 
microdissected for methylation profiling using the Illumina 800K platform. Comparison is  made 
to the pre -treatment tumor biopsy.  The Herbert Irving Comprehensive Cancer  Center 
Epi[INVESTIGATOR_532747] (led by [CONTACT_3252] -investigator Benjamin Tycko, MD, PhD)  routinely 
performs this procedure and the subsequent statistical analysis and mappi[INVESTIGATOR_532748]. Validation of up to 48 amplicons in up to 48 samples is done using  the 
Fluidigm Access Array – Illumina MiSEQ platform. Here, bisulf ite treatment and sequencing  is 
performed to validate “hits” from the methylation  array.  
 
A subsequent validation step at the transcriptional and translational level will be  performed 
82 
 based on the classes of genes identified but include one of three strate gies (1) RNASeq; (2)  Q- 
PCR; (3) immunohistochemistry or immunofluorescence on concurrent biopsy specimens.  In 
cases where sufficient quantity of tumor material is obtained to perform RNASeq analysis  this 
will be pursued. The parallel use of methylation an d expression profiling allows for the  
selection of functionally most relevant genes. Although there is support for the feasibility of  
sufficient amount of high quality RNA obtained from endoscopic biopsies to perform RNASeq 
as we  are uncertain whether in e ach case this will be feasible the alternative strategies may also 
be pursued.  
 
[IP_ADDRESS]  Immune  phenotypi[INVESTIGATOR_532749]1 or PDL1 positive cells. We have recently shown  and 
validated the ability to score expression of epi[INVESTIGATOR_532750]. We therefore will evaluate the expression of  the 
ratio of CD8/CD3 T cell s, CD86/CD68 macrophages and PD1 and PD1L expression  using 
immunohistochemistry.  
 
The ratio of CD8/CD3 TILs and CD86/CD68 macrophages will be calculated and expressed as  
a continuous variable with mean, median, and standard deviation calculations reported.  We will 
compare pre - and post -treatment CD8/CD3 and CD86/CD68 ratios using a paired t -test or  a 
nonparametric test based on the data  distribution.  
 
PD-L1 expression at baseline will be quantified as a dichotomous variable (>1%  expression  
 
considered positive, <1% considered negative). PD -L1 expression is reported to be higher  in 
81% of pancreatic tumors in historical controls than in paired non -malignant  samples26. 
Correlation between baseline PD -L1 expression (positive vs. negative) and re sponse to  therapy 
(patients with clinical benefit, as defined by [CONTACT_532800], and  
those without clinical benefit) will be analyzed using frequency tables and Fisher’s exact  test. 
 
 
13.7. Unblinding Procedures  
N/A- this is not a blin ded study.  
 
13.8. Stoppi[INVESTIGATOR_532751]:  
 
• Unacceptable aggregate toxicity as determined by [CONTACT_20767]’s Sponsor in consultation 
with the  trial’s DSMC  
• Quality or quantity of data recording is inaccurate or  incomplete  
• Poor adherence to protocol and regulatory  requirements  
• Incidence or severity of adverse drug reaction in this or other studies indicates a  
potential health hazard to  subjects  
• Plans to modify or discontinue the developm ent of the study  drug 
 
[ADDRESS_691814] treatment can be  made.  
 
 
14. DATA REPORTING / REGULATORY  REQUIREMENTS  
 
14.1. Data Collection  
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section  10.0 
(Adverse Events: List and Reporting Requirements). The Data Safety Monitoring Plan  is 
described in Section  14.3. 
 
The Herbert Irving Comprehensive Cancer Center has an electronic clinical trials and  data 
management system (CTMS) that will be used for data collection. CRFs for the study will  be 
built into the CTMS for data entry. The system has full auditing capabilities which is  web-based 
and housed on a server in a fully HIPAA compliant server room with restricted access and  video 
camera monitoring.  All users must login with their own application username [CONTACT_532815] d. 
Users off campus must first access the Virtual Private Network with their assigned  campus 
username [CONTACT_141846]. Users are only able to  see 
study information if they are indicated as study personnel in our electronic IRB system. Users  
are limited to access based on the role assigned in their corresponding protocol. Subject data  is 
entered directly into the system, which (in the case of Columbia subjects) confirms the  correct 
identity of patients via an inter face with the electronic medical patient index. Staff with  the 
appropriate IRB defined roles can run reports within the system for reporting  purposes.  
 
14.2. Data Reporting  
Case Report Forms will be completed for each subject enrolled into the clinical study thr ough  
the CTMS. It is the investigator’s responsibility for ensuring that all clinical and laboratory  data 
 
entered on the corresponding CRFs are complete, accurate and  authentic.  
 
14.3. Data and Safety Monitoring Committee  
The NCI -approved Data Safety and Monito ring Committee (DSMC) of the Herbert  Irving 
Comprehensive Cancer Center (HICCC) will monitor every subject who receives treatment  on 
this protocol for toxicity. This protocol will adhere to the policies of the currently  approved 
HICCC Data and Safety Monit oring Plan (DSMP), which is in accordance with NCI  and 
CUMC -IRB policy and guidelines. The committee is chair is appointed by [CONTACT_532801]. 
The committee consists of HICCC faculty and staff with expertise in oncology,  research 
pharmacy, research nursing, and data management. The DSMC convenes twice a month  to 
review patient safety and the conduct of the trial. The PI [INVESTIGATOR_532752] a frequency to be determined by [CONTACT_532802].  
 
At the time of renewal, the study team will submit the most recent DSMC approval letter  for 
safety review to the CUMC IRB. Any modifications that are required by [CONTACT_532803]. All protocol devia tions, violations, and  eligibility 
[ADDRESS_691815] on a  given 
date. It will summarize the DSMC’s review of the cumulative toxicities reported from  all 
participating sites without specific disclosure by [CONTACT_2939]. It will also inform  site 
investigators of the study the DSMC’s conclusion with respect to progress or ne ed for 
modification of the  protocol.  
 
14.4. Quality Control and Quality Assurance  
Independent monitoring of the clinical study for protocol and GCP compliance will be  
conducted periodically by [CONTACT_532804]. 
Additionally,  the Compliance Oversight Committee of the IRB at Columbia University Medical 
Center may  audit the study at any time per institutional policies and procedures. The 
investigator -sponsor  and Columbia University Medical Center will permit direct access of the 
study monitors  and appropriate regulatory authorities to the study data and to the corresponding 
source data  and documents to verify the accuracy of this  data.  
 
A risk -based approach will be used by [CONTACT_532805],  number 
of subject  charts,  and data elements  to be monitored.  The Compliance  Coordinator  will review  the 
study  status  and summarize  enrollment,  toxicities,  SAEs/UPs,  dose escalation,  statistical  endpoints 
(e.g., stoppi[INVESTIGATOR_004]), etc. for the full DSMC membership at the regularly scheduled  meetings.  
 
Internal On -site Monitoring:  
 
• Initial, recurrent, and close -out on -site monitoring visits will also be conducted at  
remote clinical sites, as appropriate/feasible. Other sites will have monitoring  
performed remotely (see below for further  details).  
• The study Monitoring Visit Log will be completed and signed by [CONTACT_532806]/CRNP/CRN and/or CRC and will be filed in the regulatory  binder.  
• The Compliance Coordinator will communicate  with the site coordinator/Site  Principle 
Investigator to schedule the monitoring visit and arrange for access to study  materials 
and documentation.  
• The assigned Compliance Coordinator will monitor IIT trials within [ADDRESS_691816] is enrolled and throughout the life of the study to ensure that the study  is 
being conducted in accordance with the protocol, GCP, applicable federal and  local 
regulations, and per all applicable SOPs. The Compliance Coordinator is responsible  to 
notify the P I and CRNP/CRN/CRC of upcoming monitor visits and convey  what 
information and documentation will be required for the visit(s). The  Compliance 
Coordinator is responsible for verifying that informed consent is properly  obtained, 
eligibility is met (via the c entral registration process), and all study procedures  are 
conducted according to the study protocol. The Compliance Coordinator will also  verify 
85 
 that the data reported in the CRF’s accurately reflect source documents, that all  toxicities 
have been reporte d to date, and that all SAE’s/UPs/deviations/violations have  been 
reported according to local IRB and HICCC DSMC requirements. The  Compliance 
Coordinator will issue queries and ensure resolution in a timely and efficient  manner. 
The Compliance Coordinator will also monitor for applicable regulatory compliance  and 
research pharmacy compliance (if applicable) and communicate any deficiencies  as 
appropriate.  
 
14.5. Confidentiality  
Information about study subjects will be kept confidential and managed acc ording to  the 
requirements of the Health Insurance Portability and Accountability Act (HIPAA).  Those 
regulations require a signed subject authorization informing the subject of the  following:  
• What protected health information (PHI) will be collected from s ubjects in this  study  
• Who will have access to that information and  why 
• Who will use or disclose that  information  
• The rights of a research subject to revoke their authorization for use of their  PHI. 
 
In the event that a subject revokes authorization to collect or use PHI, the investigator,  by 
[CONTACT_5151], retains the ability to use all information collected prior to the revocation of  subject 
authorization. For subjects that have revoked authorization to collect or use PHI,  attempts 
should  be made to obtain permission to collect at least vital status (e.g., that the subject is  alive) 
at the end of their scheduled study  period.  
The subject binders will be maintained with in the CPDM offices, a secured floor within  the 
 
Herbert Irving Pavilion and only the investigator and study staff will have access to the  file. 
 
14.6. Source Documents  
Source  data is all information,  original  records  of clinical  findings,  observations,  or other  activities 
in a clinical trial necessary for the reconstruction  and evaluation of the trial. Source data  are 
contained in source documents Examples of these original documents, and data records  include: 
hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjects’ diaries  or 
evaluation checklists, pharmacy dispensing records, recorded data from automated  instruments, 
copi[INVESTIGATOR_532753],  microfiches, 
photographic  negatives,  microfilm  or magnetic  media,  x-rays,  subject  files, and records  kept at the 
pharmacy, at the laboratories, and at medico -technical departments involved  in the clinical  trial. 
 
14.7. Case Report Forms  
The study  case report  form  (CRF)  is the primary  data collection  instrument  for the study.  All data 
requested  on the CRF  must  be recorded.  All missing  data must  be explained.  If a space  on the CRF 
is left blank because the procedure was not done or the question was not asked, write “N/D”.  If 
the item is not applicable to the individual case, write  “N/A”.  
 
14.8. Records Retention  
[ADDRESS_691817] three years after completion of the research  (45 
CFR 46.115(b); 21 CFR 56.115(b); 21 CFR 312.62). This minimum retention period  applies 
whether or not any subjects were enrolled in the  study.  
 
If the research is FDA regulated, records should be retained for at least two years after  approval 
of the investigational agent by [CONTACT_8415]; if it is not approved, records should be retained at least  two 
years after the study is terminated and FDA is notified (note the additional requirement below  
for clinical research  studies).  
 
Clinical records, including consent forms that document clinical intervention or clinical 
diagnostic procedure research -related procedures, must be retained in medical records by  [CONTACT_532807], per CUMC and NYP policy which is based on state  law. 
 
 
15. STATISTICAL  CONSIDERATIONS  
 
15.1. Statistical Analysis Plan  Summary  
 
This statistical analysis plan was developed in collaboration with the study statistician,  Shing 
Lee, Ph.D.  
 
15.2. Populations for Statistical Analysis and Reporting  
15.2.[ADDRESS_691818] 5 doses of azacitidine and 1 dose of pembrolizumab and completed the  DLT 
observation period (6 weeks), and those who did not complete the DLT observation period  and 
discontinued from study treatment due to a DLT event. The DLT Evaluable Population will  be 
used for DLT  assessments.  
 
 
15.2.[ADDRESS_691819] one dose of pembrolizumab, and  
will be used for the analysi s of the safety  data.  
 
15.2.3  Efficacy  Population  
Evaluable for PFS - primary outcome: All subjects who receive a single dose of protocol  therapy 
will be included in the primary outcome analysis of PFS. If subjects are removed from  study 
prior to completing a single dose of pembrolizumab, they will be replaced but will be included  
in the primary  analysis.  
 
Evaluable for objective response: Only those patients who have measurable disease present  at 
baseline, have received at least one cycle of thera py, and have had their disease re -evaluated  
[ADDRESS_691820] their response  classified 
according to the definitions stated below. (Note: Patients who exhibit objective  disease 
progression prior to the end  of cycle 1 will also be considered  evaluable.)  
 
15.2.4  Reporting of  Outcomes  
All conclusions should be based on all eligible patients. Sub analyses may then be performed  on 
the basis of a subset of patients, excluding those for whom major protocol deviations hav e been 
identified (e.g., early death due to other reasons, early discontinuation of treatment,  major 
protocol violations, etc.). However, these sub analyses may not serve as the basis for  drawing 
conclusions concerning treatment efficacy, and the reasons f or excluding patients from  the 
analysis should be clearly reported.  The 95% confidence intervals should also be  provided.  
 
15.3. Study Design/Endpoints  
15.2.[ADDRESS_691821] -line therapy in metastatic pancreatic cancer. The recently completed  cooperative 
group study (SWOG S11156) was designed to evaluate an experimental therapy compared  to 
standard chemotherapy with a null hypothesis of median PFS of [ADDRESS_691822] 80% power to detect a median PFS of 2 months in historical  controls 
versus 4 months with one -sided alpha of  0.05.  
 
 
The Kaplan -Meir method will be used to evaluate all time to event endpoints.  Median 
progression -free survival will be reported with 95% confidence  intervals.  
 
15.2.6  Secondary  Endpoints  
The secondary hypothesis of this study is that combination therapy will lead to improvements  in 
overall response rate (ORR), duration of response (DOR), disease control rate (DCR),  and 
overall survival (OS). These will all be reported with percentages and 95% confidence  intervals. 
The Kaplan -Meir method will be used to evaluate all time to event  endp oints.  
 
[IP_ADDRESS]  Definition of secondary  endpoints:  
▪ Objective Response  Rate  
o ORR is defined as the proportion of the subjects in the analysis population  who 
have a CR or PR. Responses are based on assessments per RECIST 1.1  as 
described in Sec tion 13.4. 
88 
 ▪ Duration of  Response  
o For subjects who demonstrate CR or PR, based on assessments per RECIST  1.1, 
DOR is defined as the time from first documented evidence of CR or PR  until 
disease progression or death due to any cau se, whichever occurs  first. 
▪ Disease Control  Rate  
o DCR is defined as the percentage of subjects who have achieved CR, PR, or  SD 
based on assessments per RECIST  1.1. 
▪ Overall Survival  (OS)  
o OS is defined as the time from first dose of study medication to death due to  any 
cause.  
 
15.2.[ADDRESS_691823] disease or clinical progression precluding biop sies we estimate that 
we will obtain on -treatment biopsy samples from a minimum of 20  subjects.  
[IP_ADDRESS]  Global DNA Methylation will be assessed in all subjects at baseline and every  [ADDRESS_691824] 8 weeks of study. We will estimate the disease control  rates  
(DCR) and time to event endpoints (median PFS and median OS) for  subjects 
who have methylation below the median compared to above the median  at 
baseline. We will also estimates these outcomes for those who achieve  low 
methylation (<10% methylation) compared to normal methylation  (≥10% 
methylation) after 8 weeks of therapy. We will also estimates these outcomes  for 
those who achieve a change in methylation greater than the median compared  to 
higher than the median at 8 weeks (compared to  baseline).  
 
[IP_ADDRESS]  Fisher’s exact test will be performed to compare the disease control rate for  the 
two groups. Kaplan -Meier estimates of the survival distribution for the  two 
groups will be calculated, and the two groups will be compared using a  log-rank 
test. Change in methylation in tumor tissue will be evaluated in [ADDRESS_691825] 80% power to detect a change of 0.[ADDRESS_691826] 
deviations given an alpha of  0.05.  
 
[IP_ADDRESS]  Change in methylation in tumor tissue will be evaluated in subjects who  undergo 
baseline and week 8 biopsies. We will describe changes in specific  gene 
methylation patterns as described in Section  13.6. 3. 
 
[IP_ADDRESS]  Immune phenotypi[INVESTIGATOR_532754]- 
treatment tumor biopsy. We will p rovide descriptive tables of IHC expression  of 
CD8/CD3 T cell ratio, CD86/CD68 macrophage ratio, PD1 expression.  Samples 
will be compared between pre and post combination specimens in  treated 
subjects using the paired  t-test. 
15.4. Size/Accrual Rate  
A total of 31 subjects will be enrolled over 18 months with plan to screen 4 -5 subjects in  our 
89 
 multi -disciplinary pancreas clinic each month with enrollment of 2 -3 patients per month. If  the 
original 6 patient DLT cohort requires a dose reduction then up to a maximum  of 37 subjects  
will be enrolled with 31 additional enrolled at the final dose  level.  
 
15.5. Stratification Factors  
No stratification is  planned.  
 
15.6. Statistical Methods for Safety Analysis  
Safety and tolerability will be assessed by [CONTACT_532808] (AEs), laboratory tests, and vital signs. Count and percentage AE will  be 
provided. Confidence interval rate of AE of clinical interest will be estimated using  Exact 
method based on binomial  distribution.  
 
15.7. Analysis Populations  
All subjects who received at least one dose of study treatment will be included in the  primary 
and secondary efficacy and safety analysis as detailed in Section  15.2. 
 
 
16. PROT ECTION  OF HUMAN  SUBJECTS  
This study is to be conducted in accordance with applicable government regulations  and 
Institutional research policies and  procedures.  
 
This protocol and any amendments will be submitted to a properly constituted  Institutional 
Review Board (IRB), in agreement with local legal prescriptions, for formal approval of  the 
study conduct. The decision of the IRB concerning the conduct of the study will be made  in 
writing to the investigator and a copy of this decision wil l be obtained before commencement  of 
this study.  
 
 
All subjects for this study will be provided a consent form describing this study and  providing 
sufficient information for subjects to make an informed decision about their participation in  
this study. This consent form will be submitted with the protocol for review and approval by 
[CONTACT_14884]. The formal consent of a subject, using the IRB -approved consent form, 
must  be obtained before that subject is submitted to any study procedu re. This consent form 
must  be signed by [CONTACT_17257], as outlined in the IRB approved  
protocol, and the investigator -designated research professional obtaining the  consent.  
 
 
17. STUDY FINANCES  
 
17.1. Conflict of  Interest  
 
 N/A 
 
17.[ADDRESS_691827] Stipends or  Payments  
90 
  
 N/A 
 
18. PUBLICATION PLAN  
 
Neither the complete nor any part of the results of the study carried out under this 
protocol,  nor any of the information provided by [CONTACT_440637], will  be published or passed on to  any third party  without the 
consent of the study  sponsor. Any  investigator involved with this study is obligated to 
provide the sponsor with complete  test results and all data derived from the  study.  
 
19. REFERENCES  
 
1. Cohen AL, Ray A, Van Brocklin M, et al. A phase I trial of azacitidine and  nanoparticle 
albumin bound paclitaxel in patients with advanced or metastatic solid  tumors. 
Oncotarget. Dec [ADDRESS_691828] 31 
2013;369(18):[ADDRESS_691829] S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine  vs 
observation in patients undergoing curative -intent resection of pancreatic cancer:  a 
randomized controlled trial. JAMA : the journal of the American Medical  Association. 
Jan 17  2007;297(3):267 -277. 
5. Sohal DP, Walsh RM, Ramanathan RK, Khorana AA. Pancreatic  adenocarcinoma: 
treating a systemic disease with systemic therapy. J Natl Cancer Inst.  Mar 
2014;106(3):dju011.  
6. Chung V, McDonough S, Philip PA, et al. Effect of Selumetinib and MK-2206  vs 
Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After  Prior 
Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA oncology. Dec 15  
2016.  
7. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8( +) T- 
lymphocytes as a prognostic factor in human renal cell carcinoma:  clinicopathologic 
demonstration of antitumor immunity. Cancer Res. Jul 1  2001;61(13):[ADDRESS_691830] survival in human pleural  mesothelioma. 
Cancer. Nov 15  2011;117(22):5234 -5244.  
9. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD -L1 in  lung 
cancer may contribute to poor prognosis and tumor cells immune escape  through 
suppressing tumor infiltrating dendritic cells maturation. Medical oncology.  Sep 
2011;28(3):682 -688. 
10. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory molecule B7 -H1 in  
primary and metastatic clear cell renal cell  carcinoma. Cancer. Nov 15  
2005;104(10):2084 -2091.  
11. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7 -H1 is associated with  poor 
91 
 prognosis in renal cell carcinoma patients with long -term follow -up. Cancer Res. Apr 1 
2006;66(7):3381 -3385.  
12. Krambeck AE, Dong H, Thompson RH, et al. Survivin and b7 -h1 are  collaborative 
predictors of survival and represent potential therapeutic targe ts for patients with  renal 
cell carcinoma. Clin Cancer Res. Mar 15  2007;13(6):1749 -1756.  
13. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of  the 
programmed death -1 ligand/programmed death -[ADDRESS_691831] in human pancreatic  cancer . 
Clinical cancer research : an official journal of the American Association for  Cancer 
Research. Apr 1  2007;13(7):2151 -2157.  
14. Loos M, Giese NA, Kleeff J, et al. Clinical significance and regulation of  the 
costimulatory molecule B7 -H1 in pancreatic cancer. Cancer letters. Sep 8 
2008;268(1):98 -109. 
15. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and  tumor - 
 
infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian  cancer. 
Proceedings of the National Academy of Sciences of the [LOCATION_002] of America. Feb 
27 2007;104(9):3360 -3365.  
16. Andorsky DJ, Yamada RE, Said J, Pi[INVESTIGATOR_66822], Betting DJ, Timmerman JM.  
Programmed death ligand 1 is expressed by [CONTACT_105]-hodgkin lymphomas and inhibits the 
activity  of 
tumor -associated T cells. Clin Cancer Res. Jul 1  2011;17(13):4232 -4244.  
17. Brusa D, Serra S, Coscia M, et al. The PD -1/PD -L1 axis contributes to T -cell 
dysfunction in chronic lymphocytic leukemia. Haematologi ca. Jun 2013;98(6):953 -963. 
18. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD -1 and its ligands in tolerance  and 
immunity. Annual review of immunology.  2008;26:677 -704. 
19. Park JJ, Omiya R, Matsumura Y, et al. B7 -H1/CD80 interaction is required for  the 
induction a nd maintenance of peripheral T -cell tolerance. Blood. Aug 26 
2010;116(8):1291 -1298.  
20. Zou W, Chen L. Inhibitory B7 -family molecules in the tumour microenvironment.  Nat 
Rev Immunol. Jun 2008;8(6):467 -477. 
21. Weber JS, Kahler KC, Hauschild A. Management of immune -related adverse events  and 
kinetics of response with ipi[INVESTIGATOR_125]. Journal of clinical oncology : official journal of  
the American Society of Clinical Oncology. Jul 20  2012;30(21):2691 -2697.  
22. McDermott DF. Immunotherapy of metastatic renal cell carcino ma. Cancer. May 15 
2009;115([ADDRESS_691832]):2298 -2305.  
23. Kresowik TP, Griffith TS. Bacillus Calmette -Guerin immunotherapy for  urothelial 
carcinoma of the bladder. Immunotherapy. Mar 2009;1(2):281 -288. 
24. Bograd AJ, Suzuki K, Vertes E, et al. Immune responses and  immunotherapeutic 
interventions in malignant pleural mesothelioma. Cancer immunology, immunotherapy  : 
CII. Nov 2011;60(11):1509 -1527.  
25. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of  
anti- PD-1 antibody in cancer. The New  England journal of medicine. Jun 28 
2012;366(26):2443 -2454.  
26. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated  melanoma 
without BRAF mutation. The New England journal of medicine. Jan 22  
2015;372(4):320 - 330. 
27. Weber JS, D'Angelo SP, Minor  D, et al. Nivolumab versus chemotherapy in patients  
92 
 with advanced melanoma who progressed after anti -CTLA -4 treatment (CheckMate 
037):  a randomised, controlled, open -label, phase 3 trial. Lancet Oncol. Apr 
2015;16(4):375 -384. 
28. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in  Advanced 
Squamous -Cell Non -Small -Cell Lung Cancer. The New England journal of  medicine. 
May 31  2015.  
29. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of  non-small -cell 
lung cancer. The New Engla nd journal of medicine. May 21  2015;372(21):2018 -2028.  
30. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipi[INVESTIGATOR_532755]. The New England journal of medicine. Jun 25  2015;372(26):2521 -2532.  
31. Motzer RJ, Rini BI, McDermott DF, et al.  Nivolumab for Metastatic Renal  Cell 
Carcinoma: Results of a Randomized Phase II Trial. Journal of clinical oncology  : 
official journal of the American Society of Clinical Oncology. May 1  2015;33(13):1430 - 
1437.  
32. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipi[INVESTIGATOR_125]  (anti-CTLA -
4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother.  Oct 
2010;33(8):828 -833. 
33. Cheng X, Blumenthal RM. Mammalian DNA methyltransferases: a  structural 
perspective. Structure. Mar 2008;16(3):[ADDRESS_691833] AP. CpG islands and genes. Curr Opin Genet Dev. Jun 1995;5(3):309 - 
314. 
35. Jones PA, Baylin SB. The epi[INVESTIGATOR_308038]. Cell. Feb 23  2007;128(4):[ADDRESS_691834] 2011;11(10):726 -734. 
37. Singh M, Maitra A. Precursor lesions of pancreatic cancer: molecular pathology  and 
clinical implications. Pancreatology.  2007;7(1):9 -19. 
38. Rosty C, Geradts J, Sato N, et al. p16 Inactivation in pancreatic intraepi[INVESTIGATOR_532756] 
(PanINs) arising in patients with chronic pancreatitis. Am J Surg Pathol.  Dec 
2003;27(12):1495 -1501.  
39. Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for  aberrant 
meth ylation in pancreatic carcinoma using high -throughput microarrays. Cancer Res.  Jul 
1 2003;63(13):3735 -3742.  
40. Li H, Chiappi[INVESTIGATOR_108639], Guzzetta AA, et al. Immune regulation by [CONTACT_532809] 5 -azacitidine in common human epi[INVESTIGATOR_532757]. 
Oncotarget. Feb 15  2014;5(3):587 -598. 
41. Kim K, Skora AD, Li Z, et al. Eradication of metastatic mouse cancers resistant  to 
immune checkpoint blockade by [CONTACT_108694] -derived cells. Proceedings  of 
the National Academy of Sciences  of the [LOCATION_002] of America. Aug 12 
2014;111(32):[ZIP_CODE] -[ZIP_CODE].  
42. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen Y -T. Cancer/testis antigens:  an 
expanding family of targets for cancer immunotherapy. Immunological  Reviews. 
2002;188(1):22 -32. 
43. James SR, Link PA, Karpf AR. Epi[INVESTIGATOR_532758] X -linked  cancer/germline 
antigen genes by [CONTACT_532810]1 and DNMT3b. Oncogene. Nov 2  2006;25(52):[ADDRESS_691835]: IFNgamma -mediated MHC class I upregulation on tumour cells  is 
associated with DNA demethylation of antigen -presenting machinery genes.  Oncotarget. 
93 
 Aug 30  2014;5(16):6923 -6935.  
45. Toor AA, Payne KK, Chung HM, et al. Epi[INVESTIGATOR_532759]: sequential azacitidine and lenalidomide generate  cancer 
testis antigen -specific cellular immunity. British journal of haematology.  Sep 
2012;158(6):700 -711. 
46. Weber J, Salgaller M, Samid D, et al. Expression of the MAGE -1 tumor antigen is  up- 
regulated by [CONTACT_532811] 5 -aza-2'-deoxycytidine. Cancer Res. Apr 1 
1994;54(7):1766 -1771.  
47. Dubovsky JA, McNeel DG. Inducible expression of a prostate cancer -testis antigen,  
SSX- 2, following treatment with a DNA methyl ation inhibitor. The Prostate. Dec 1 
2007;67(16):1781 -1790.  
48. Smith HA, Cronk RJ, Lang JM, McNeel DG. Expression and  immunotherapeutic 
targeting of the SSX family of cancer -testis antigens in prostate cancer. Cancer Res.  Nov 
1 2011;71(21):6785 -6795.  
49. Rao M, Chinnasamy N, Hong JA, et al. Inhibition of histone lysine methylation  
enhances cancer -testis antigen expression in lung cancer cells: implications for  adoptive 
immunotherapy of cancer. Cancer Res. Jun 15  2011;71(12):4192 -4204 . 
50. Wrangle J, Wang W, Koch A, et al. Alterations of immune response of Non -Small  Cell 
Lung Cancer with Azacytidine. Oncotarget. Nov 2013;4(11):2067 -2079.  
51. Gettinger SN, Kowanetz M, Koeppen H, et al. Molecular, immune and  histopathological 
characterization of  NSCLC based on PDL1 expression on tumor and immune cells  and 
association with response to the anti -PDL1 antibody MPDL3280A. ASCO  Meeting 
Abstracts. May 18, 2015  2015;33(15_suppl):3015.  
52. Yang H, Bueso -Ramos C, DiNardo C, et al. Expression of PD -L1, PD-L2, PD -1 and 
CTLA4 in myelodysplastic syndromes is enhanced by [CONTACT_532812]. Leukemia. Jun 2014;28(6):1280 -1288.  
53. Shakya R, Gonda T, Quante M, et al. Hypomethylating therapy in an aggressive  stroma - 
rich model of pancreatic carci noma. Cancer Res. Jan 15  2013;73(2):[ADDRESS_691836] supportive care  in 
elderly patients with intermediate - or high -risk myelodysplastic syndrome  (MDS) 
ineligible for intensive chemotherapy: final results of the randomized phase III study  of 
the European Organisation for Research and Treatment of Cancer Leukemia Group  and 
the German MDS Study Group. Journal of clinical oncology : official journal of  the 
American Society of Clinic al Oncology. May 20  2011;29(15):1987 -1996.  
55. Fenaux P, Mufti GJ, Hellstrom -Lindberg E, et al. Efficacy of azacitidine compared  with 
that of conventional care regimens in the treatment of higher -risk myelodysplastic 
syndromes: a randomised, open -label, phase III study. Lancet Oncol.  Mar 
2009;10(3):223 -232. 
56. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epi[INVESTIGATOR_532760] -small cell lung cancer. Cancer discovery.  Dec 
2011;1(7):598 -607. 
57. Disis ML. Immune regulation of cancer. Journal of clinical oncology : official journal  of 
the American Society of Clinical Oncology. Oct 10  2010;28(29):[ADDRESS_691837], et al. Tumor -associated B7 -H1 promotes  T-cell 
apoptosis: a potential mechanism of immune evasion. Nature medicine.  Aug 
2002;8(8):793 -800. 
94 
 59. Sharpe AH, Freeman GJ. The B7 -CD28 superfamily. Nature reviews. Immunology.  Feb 
2002;2(2):116 -126. 
60. Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed dea th-1 ligands  on 
dendritic cells enhances T cell activation and cytokine production. Journal  of 
immunology. Feb 1  2003;170(3):1257 -1266.  
61. Thompson RH, Dong H, Lohse CM, et al. PD -1 is expressed by  [CONTACT_20150] -infiltrating 
immune cells and is associated with poor outcome for patients with renal cell  carcinoma. 
Clinical cancer research : an official journal of the American Association for  Cancer 
Research. Mar 15  2007;13(6):1757 -1761.  
62. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Je kyll or 
Hyde. Cancer metastasis reviews. Dec 2007;26(3 -4):373 -400. 
63. Hodi FS, Dranoff G. The biologic importance of tumor -infiltrating lymphocytes.  Journal 
of cutaneous pathology. Apr 2010;[ADDRESS_691838]  1:48-53. 
64. Lee HE, Chae SW, Lee YJ, et al. Prognostic implications of type and density of  tumour - 
 
infiltrating lymphocytes in gastric cancer. British journal of cancer. Nov 18 
2008;99(10):1704 -1711.  
65. Leffers N, Gooden MJ, de Jong RA, et al. Prognostic significance of tumor -infiltrating  
T- lymphocyt es in primary and metastatic lesions of advanced stage ovarian cancer.  
Cancer immunology, immunotherapy : CII. Mar 2009;58(3):449 -459. 
66. Hiraoka N. Tumor -infiltrating lymphocytes and hepatocellular carcinoma:  molecular 
biology. International journal of clinical oncology. Dec 2010;15(6):544 -551. 
67. Polcher M, Braun M, Friedrichs N, et al. Foxp3(+) cell infiltration and  granzyme 
B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant  chemotherapy - 
treated ovarian carcinoma . Cancer immunology, immunotherapy : CII.  Jun 
2010;59(6):909 -919. 
68. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD -1 immunoreceptor  
inhibits B  cell receptor -mediated  signaling  by [CONTACT_323835]  2-domain -
containing  tyrosine phosphatase 2 to phosphotyrosine. Proceedings of the National 
Academy  of Sciences of the [LOCATION_002] of America. Nov 20  2001;98(24):[ZIP_CODE] -
[ZIP_CODE].  
69. Karpf AR, Peterson PW, Rawlins JT, et al. Inhibition of DNA  methyltransferase 
stimulates the express ion of signal transducer and activator of transcription 1, 2, and  3 
genes in colon tumor cells. Proceedings of the National Academy of Sciences of  the 
[LOCATION_002] of America. Nov 23  1999;96(24):[ZIP_CODE] -[ZIP_CODE].  
70. Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA. Limited  gene 
activation in tumor and normal epi[INVESTIGATOR_532761] 5 -aza-2'-deoxycytidine. Molecular pharmacology. Jan 2004;65(1):18 -27. 
71. Matei D, Fang F, Shen C, et al. Epi[INVESTIGATOR_532762].  
Cancer research. May 1  2012;72(9):[ADDRESS_691839] A, et al. Inhibiting DNA Methylation Causes  an 
Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell.  Aug 
27 2015;162(5):974 -986. 
73. Nishino M, Giobbie -Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS.  Developi[INVESTIGATOR_007] 
a common language for tumor response to immunotherapy: immune -related  response 
criteria using unidimensional measurements. Clinical cancer research : an  official 
journal of the American Association for Cancer Research. Jul 15  2013;19(14):3936 - 
95 
 3943.  
74. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in  solid 
tumours: revised RECIST guideline (version 1.1). European journal of c ancer.  Jan 
2009;45(2):228 -247. 
75. Bohnsack O, Hoos A, Ludajc K. Adaptation of the Immune Related Response  Criteria: 
IRRECIST. Annals of Oncology. 2014;25 (Supplement  4):iv369.  
 
 
 
 
 
20. APPENDICES  
 
20.1. Appendix 1 - ECOG Performance Status  
 
Grade  Description  
0 Normal activity. Fully active, able to carry on all pre -disease performance without  restriction.  
 
1 Symptoms, but ambulatory. Restricted in physically strenuous activity, but ambulatory  and 
able to carry out work of a light or sedentary nature (e.g., light housework, office  work).  
 
2 In bed <50% of the time. Ambulatory and capable of all self -care, but unable to carry out  any 
work activities. Up and about more than 50% of waking  hours.  
 
3 In bed >50% of the time. Capable of only limited self-care, confined to bed or chair  more 
than 50% of waking  hours.  
 
4 100% bedridden. Completely disabled. Cannot carry on any self -care. Totally confined to  bed 
or chair.  
5 Dead.  
 
 
 
 
20.2. Appendix 2 - Common Terminology Criteria for Adverse Events V4.0 (CTCAE)  
The descriptions and grading scales found in the revised NCI Common 
Terminology Criteria  for Adverse Events (CTCAE) version 4.0 will be utilized 
for adverse event  reporting.  
 
http://www.oncology.tv/SymptomManagement/NationalCancerInstituteUpdatesC
TCAEtov403.a  spx 
 
20.3. Appendix 3 - Response Evaluation Criteria in Solid Tumors (RECIST) 1.[ADDRESS_691840] is the preferred imaging technique in this  study.  
 
In addition, volumetric analysis will be explored for response  assessment.  
 
 